Browse the corpus

Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.

• "You have not remained the same, nor have I".9 passages
• 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study.51 passages
• 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.1 passage
• 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.1 passage
• 18F-fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine.4 passages
• 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial.1 passage
• 2021: a year in review.11 passages
• 2021: the beginning of a new era of immunisations?5 passages
• 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.1 passage
• 5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial.1 passage
• 5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.1 passage
• 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.45 passages
• 7-1-7: an organising principle, target, and accountability metric to make the world safer from pandemics.14 passages
• 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.1 passage
• A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.1 passage
• A 3-year review of deaths in people under community justice supervision in Wales: a cross-sectional analysis.1 passage
• A WHO pandemic instrument: substantive provisions required to address global shortcomings.1 passage
• A beautiful idea: how COVAX has fallen short.18 passages
• A call for more evidence documenting human-to-dog transmission of monkeypox virus.2 passages
• A call to accelerate an end to human rabies deaths.11 passages
• A case of acute necrotising encephalitis secondary to human herpesvirus 6 infection.1 passage
• A century past the discovery of insulin: global progress and challenges for type 1 diabetes among children and adolescents in low-income and middle-income countries.1 passage
• A clinical decision tool including a decision tree, point-of-care testing of CRP, and safety-netting advice to guide antibiotic prescribing in acutely ill children in primary care in Belgium (ARON): a pragmatic, cluster-randomised, controlled trial.1 passage
• A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.1 passage
• A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.1 passage
• A contemporary review of sudden cardiac arrest and death in competitive and recreational athletes.1 passage
• A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry.1 passage
• A cross-sectional survey of the prevalence and determinants of comorbid psychological distress in attendees at two general hospitals in Gaza.1 passage
• A decade later, what have we learned from the Zika epidemic in children with intrauterine exposure?1 passage
• A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.1 passage
• A global analysis of One Health Networks and the proliferation of One Health collaborations.1 passage
• A global compact to counter vaccine nationalism.1 passage
• A legal mapping of 48 WHO member states' inclusion of public health emergency of international concern, pandemic, and health emergency terminology within national emergency legislation in responding to health emergencies.1 passage
• A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.58 passages
• A multidimensional measure of wellbeing among youth: a cross-sectional study of the Palestinian refugee youth in Lebanon.1 passage
• A multifaceted intervention to improve diagnosis and early management of hospitalised patients with suspected acute brain infections in Brazil, India, and Malawi: an international multicentre intervention study.42 passages
• A new age of precision gene therapy.1 passage
• A new strategy for health and sustainable development in the light of the COVID-19 pandemic.7 passages
• A peer-led walking intervention for adolescent girls (the WISH study): a cluster-randomised controlled trial.1 passage
• A plea for reproductive health support amid crisis in Lebanon.3 passages
• A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial.1 passage
• A reinvigorated multilateralism in health: lessons and innovations from the COVID-19 pandemic.14 passages
• A reproductive justice response to HIV/AIDS and COVID-19.9 passages
• A step backwards in the fight against global vaccine inequities.3 passages
• A strong and independent Africa CDC would benefit the world.2 passages
• A taste of your own medicine: the experience of a transplant.10 passages
• A telemedicine model for abortion in South Africa: a randomised, controlled, non-inferiority trial.1 passage
• A three-step support strategy for relatives of patients dying in the intensive care unit: a cluster randomised trial.1 passage
• A time of crisis for the opioid epidemic in the USA.5 passages
• A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.1 passage
• A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial.1 passage
• A waiting crisis?11 passages
• AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a single-arm trial.1 passage
• ACT Accelerator strains donors' aid budgets.5 passages
• ACT-A: "The international architecture did not work for us".11 passages
• ACT-A: half empty or half full?3 passages
• ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial.1 passage
• AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.1 passage
• Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.1 passage
• Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.1 passage
• Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.50 passages
• Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.1 passage
• Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.1 passage
• Accelerate investment and action to find the missing patients with tuberculosis.7 passages
• Accelerating pooled licensing of medicines to enhance global production and equitable access.12 passages
• Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK.1 passage
• Access to COVID-19 vaccines: looking beyond COVAX.5 passages
• Activity limitations, use of assistive devices, and mortality and clinical events in 25 high-income, middle-income, and low-income countries: an analysis of the PURE study.1 passage
• Acute aortic dissection.1 passage
• Acute coronary syndromes.65 passages
• Acute flaccid myelitis: cause, diagnosis, and management.1 passage
• Acute glomerulonephritis.1 passage
• Acute kidney injury.1 passage
• Acute liver failure.1 passage
• Acute lymphocytic leukaemia.1 passage
• Acute myeloid leukaemia.1 passage
• Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management.1 passage
• Acute respiratory distress syndrome.69 passages
• Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes.1 passage
• Acute rheumatic fever.1 passage
• Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.1 passage
• Adaptive deep brain stimulation in Parkinson's disease.1 passage
• Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial.1 passage
• Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.1 passage
• Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.34 passages
• Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.1 passage
• Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial.1 passage
• Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.1 passage
• Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.1 passage
• Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.1 passage
• Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.1 passage
• Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.1 passage
• Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.1 passage
• Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.1 passage
• Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.1 passage
• Adopting an intersectionality framework to address power and equity in medicine.6 passages
• Adrenal insufficiency.1 passage
• Adult epilepsy.1 passage
• Adult obesity and risk of severe infections: a multicohort study with global burden estimates.46 passages
• Advancing One human-animal-environment Health for global health security: what does the evidence say?1 passage
• Advancing accurate metrics for future pandemic preparedness.1 passage
• Advancing patient monitoring, diagnostics, and treatment strategies for transplant precision medicine.1 passage
• Adverse pregnancy outcomes attributable to socioeconomic and ethnic inequalities in England: a national cohort study.1 passage
• Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.1 passage
• Africa CDC warns COVID-19 vaccine production could cease.5 passages
• Africa needs local solutions to face the COVID-19 pandemic.7 passages
• Africa's need for more COVID-19 clinical trials.5 passages
• After 2 years of the COVID-19 pandemic, translating One Health into action is urgent.34 passages
• Age and frailty in COVID-19 vaccine development.7 passages
• Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19 - Authors' reply.2 passages
• Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19.1 passage
• Age-related macular degeneration.1 passage
• Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.39 passages
• Aggressive intraoperative warming versus routine thermal management during non-cardiac surgery (PROTECT): a multicentre, parallel group, superiority trial.1 passage
• Aid agencies turn attention to diabetes.7 passages
• Alcohol use disorders.1 passage
• Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial.1 passage
• Ali Zumla: respiratory medicine and global health supremo.5 passages
• Allocated but not treated: the silent 16% - Authors' reply.3 passages
• Allocated but not treated: the silent 16.2 passages
• Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.1 passage
• Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.1 passage
• Alzheimer's disease outlook: controversies and future directions.1 passage
• Alzheimer's disease.1 passage
• Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.1 passage
• Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?1 passage
• Amyotrophic lateral sclerosis.1 passage
• An SMS and animated video intervention to increase uptake of breast cancer screening: a randomised controlled trial.1 passage
• An action plan for pan-European defence against new SARS-CoV-2 variants.15 passages
• An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.1 passage
• An appeal for an objective, open, and transparent scientific debate about the origin of SARS-CoV-2 - Authors' reply.1 passage
• An appeal for an objective, open, and transparent scientific debate about the origin of SARS-CoV-2.1 passage
• An educational programme in neonatal intensive care units (SEPREVEN): a stepped-wedge, cluster-randomised controlled trial.1 passage
• An empowerment model for managing menopause.1 passage
• An evidence-based assessment of the impact of the Olympic Games on population levels of physical activity.1 passage
• An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.1 passage
• An open letter to the Executive Board of WHO from the surgical and anaesthesia community.3 passages
• Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial.1 passage
• Angiography-derived fractional flow reserve versus coronary angiography to guide coronary artery bypass grafting in patients undergoing surgical valve procedures with concomitant coronary artery disease in China (FAVOR IV-QVAS): a multicentre, triple-blind, randomised trial.1 passage
• Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial.1 passage
• Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.36 passages
• Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.1 passage
• Answering the call to support youth orphaned by COVID-19.5 passages
• Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.35 passages
• Anti-D immunoglobulin versus immunoglobulin G for the treatment of acute immune thrombocytopenia in children: a 10-year retrospective study.1 passage
• Anti-cytokine biologics for asthma in adults.1 passage
• Antibiotic use in acute upper respiratory tract infections and uncomplicated lacerations in the Gaza Strip: clinical audit and re-audit.1 passage
• Antibiotics for lower respiratory tract infection in children presenting in primary care in England (ARTIC PC): a double-blind, randomised, placebo-controlled trial.51 passages
• Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.5 passages
• Anticoagulation in COVID-19.7 passages
• Anticoagulation in COVID-19: reaction to the ACTION trial.6 passages
• Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series.1 passage
• Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis.36 passages
• Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials.41 passages
• Anxiety disorders.1 passage
• Appendicectomy versus antibiotics for acute uncomplicated appendicitis in children: an open-label, international, multicentre, randomised, non-inferiority trial.1 passage
• Aqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial.1 passage
• Arterial hypertension.1 passage
• Artificial intelligence-guided screening for atrial fibrillation using electrocardiogram during sinus rhythm: a prospective non-randomised interventional trial.1 passage
• Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.39 passages
• Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.1 passage
• Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial.1 passage
• Assessing COVID-19 pandemic policies and behaviours and their economic and educational trade-offs across US states from Jan 1, 2020, to July 31, 2022: an observational analysis.90 passages
• Assessing government responsibility for COVID-19 deaths.2 passages
• Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.1 passage
• Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.28 passages
• Assessment of drug interactions and their associated factors among patients with cardiovascular diseases: a cross-sectional study from the occupied Palestinian territory.1 passage
• Assessment of health-related quality of life in patients with inflammatory bowel disease in occupied Palestinian territory: a correlation cross-sectional study.1 passage
• Assessment of malnutrition in preschool-aged children by mid-upper arm circumference in the Gaza Strip (January, 2024-August, 2025): a longitudinal, cross-sectional, surveillance study.1 passage
• Assessment of pain control among patients with cancer in hospitals of the Gaza Strip: a cross-sectional study.2 passages
• Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study.37 passages
• Assessment of the influence of Facebook on eating out at fast food restaurants: a cross-sectional study of Palestinian college students.1 passage
• Assessment of the surveillance system for adverse events following immunisation in the Gaza Strip: a cross-sectional study.1 passage
• Association between care experience and mental health hospitalisation among children in Scotland, with a focus on chronic conditions (CHiCS): a population-wide longitudinal study using administrative data.1 passage
• Association between friendship quality and subjective wellbeing in adolescents: a cross-sectional observational study.1 passage
• Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants.1 passage
• Associations between parental smoking and teenage alcohol and drug use in the Growing Up in Ireland cohort study: a longitudinal observational study.1 passage
• Associations between stressful working conditions and psychosomatic symptoms among Palestinian nurses: a cross-sectional survey.1 passage
• Associations of social media use with smoking and e-cigarettes: a national longitudinal study.1 passage
• Asthma.1 passage
• Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.1 passage
• Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.1 passage
• Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.1 passage
• Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Atopic dermatitis.1 passage
• Atosiban versus placebo for threatened preterm birth (APOSTEL 8): a multicentre, randomised controlled trial.1 passage
• Atrial fibrillation.1 passage
• Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.1 passage
• Attitudes and behaviours regarding e-cigarettes in people aged 15-30 years in the UK: a cross-sectional study.1 passage
• Attitudes to long-term care in India: a secondary mixed-methods analysis.1 passage
• Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.1 passage
• Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.1 passage
• Autosomal dominant polycystic kidney disease.1 passage
• Avoiding shoulder injury from intramuscular vaccines.3 passages
• Awareness and prevalence of needle stick injuries among cleaners and health-care providers in Gaza Strip hospitals: a cross-sectional study.1 passage
• Axial spondyloarthritis.1 passage
• Ayoade Alakija: advancing equity in the COVID-19 response.5 passages
• Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.55 passages
• Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.37 passages
• Azithromycin, RECOVERY, and the power of large, simple trials.4 passages
• B-cell non-Hodgkin lymphomas.1 passage
• Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial.1 passage
• Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.1 passage
• Balloon catheters versus vaginal prostaglandins for labour induction (CPI Collaborative): an individual participant data meta-analysis of randomised controlled trials.1 passage
• Balloon guide catheters for endovascular thrombectomy in patients with acute ischaemic stroke due to large-vessel occlusion in China (PROTECT-MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.1 passage
• Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.1 passage
• Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.1 passage
• Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).1 passage
• Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).1 passage
• Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality.7 passages
• Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.1 passage
• Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.49 passages
• Bayesian reconstruction of household transmissions to infer the serial interval of COVID-19 by variants of concern: analysis from a prospective community cohort study (Virus Watch).1 passage
• Bayesian statistics for clinical research.1 passage
• Behavioural interventions to increase uptake of FIT colorectal screening in Scotland (TEMPO): a nationwide, eight-arm, factorial, randomised controlled trial.1 passage
• Behçet's syndrome.1 passage
• Benchmarking progress in non-communicable diseases: a global analysis of cause-specific mortality from 2001 to 2019.59 passages
• Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.1 passage
• Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial.1 passage
• Better informing everyday fall risk assessment: experimental studies with contemporary technologies.1 passage
• Beyond the dichotomy of drug regulations and prohibitions.2 passages
• Biden's first legislative victory: $1·9 trillion for COVID-19.12 passages
• Biliary tract cancer.1 passage
• Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.1 passage
• Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).1 passage
• Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).1 passage
• Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.1 passage
• Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.1 passage
• Biological and pathological mechanisms leading to the birth of a small vulnerable newborn.1 passage
• Biomarker risk stratification with capsule sponge in the surveillance of Barrett's oesophagus: prospective evaluation of UK real-world implementation.1 passage
• Biomedical innovations in contraception: gaps, obstacles, and solutions for sexual and reproductive health.1 passage
• Bipolar disorder.1 passage
• Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.1 passage
• Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.34 passages
• Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials.1 passage
• Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study.1 passage
• Body-mass index and diabetes risk in 57 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 685 616 adults.1 passage
• Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18.28 passages
• Booster vaccines for COVID-19 vaccine breakthrough cases?1 passage
• Booster vaccines for COVID-19 vaccine breakthrough cases? - Authors' reply.2 passages
• Boosters appear effective, but are they always needed?6 passages
• Boosting immunity after CoronaVac.1 passage
• Borderline personality disorder.1 passage
• Bottom-up citizen engagement for health emergency and disaster risk management: directions since COVID-19.10 passages
• Brain injury after cardiac arrest.1 passage
• Brazilian ICUs short of drugs and beds amid COVID-19 surge.10 passages
• Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.8 passages
• Breast cancer.1 passage
• Breastfeed or be vaccinated-an unreasonable default recommendation.3 passages
• Breastfeeding: crucially important, but increasingly challenged in a market-driven world.1 passage
• Bronchiolitis.1 passage
• Budesonide-formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial.1 passage
• Building community capacity in mental health care with the Strong Minds-Strong Communities programme: a randomised controlled trial in the USA.1 passage
• Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.142 passages
• Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis.1 passage
• Burden of disease attributable to unsafe drinking water, sanitation, and hygiene in domestic settings: a global analysis for selected adverse health outcomes.59 passages
• Burden of disease scenarios by state in the USA, 2022-50: a forecasting analysis for the Global Burden of Disease Study 2021.1 passage
• Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021.146 passages
• Burr-hole drainage with or without irrigation for chronic subdural haematoma (FINISH): a Finnish, nationwide, parallel-group, multicentre, randomised, controlled, non-inferiority trial.1 passage
• Business leaders' perceptions of how workplace charters can reduce health inequalities for employees in West Yorkshire, England: a qualitative study.1 passage
• Buyer beware: inflated claims of sensitivity for rapid COVID-19 tests.4 passages
• CAR T-cell therapy in autoimmune diseases.1 passage
• CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.1 passage
• CEPI criticised for lack of transparency.11 passages
• CEPI launches 100-day vaccine "moonshot".10 passages
• CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis.1 passage
• CONSORT 2025 statement: updated guideline for reporting randomised trials.1 passage
• COV-BOOST: evidence to support rapid booster deployment.1 passage
• COVID duets.12 passages
• COVID-19 ARDS: getting ventilation right - Authors' reply.1 passage
• COVID-19 and disparities affecting ethnic minorities.6 passages
• COVID-19 and inter-generational solidarity.1 passage
• COVID-19 and microbiome diversity in sub-Saharan Africa - Author's reply.2 passages
• COVID-19 and microbiome diversity in sub-Saharan Africa.2 passages
• COVID-19 and other adult vaccines can drive global disease prevention.1 passage
• COVID-19 and other pandemics require a coherent response strategy.6 passages
• COVID-19 and the Swedish enigma.7 passages
• COVID-19 and the moral imagination.7 passages
• COVID-19 and the rebiologisation of racial difference.9 passages
• COVID-19 and the role of Voluntary, Community, and Social Enterprises in northern England in responding to the needs of marginalised communities: a qualitative focus group study.1 passage
• COVID-19 booster doses in pregnancy and global vaccine equity.5 passages
• COVID-19 boosters and building trust among UK minority ethnic communities.6 passages
• COVID-19 highlights Canada's care home crisis.5 passages
• COVID-19 in Africa: a lesson in solidarity.5 passages
• COVID-19 in Brazil: far beyond biopolitics.4 passages
• COVID-19 in Europe: new challenges for addressing vaccine hesitancy.1 passage
• COVID-19 in Latin America-emergency and opportunity.5 passages
• COVID-19 in North Korea.5 passages
• COVID-19 in Turkey: a nation on edge.15 passages
• COVID-19 infection, reinfection, and the transition to endemicity.6 passages
• COVID-19 mRNA vaccination and myocarditis or pericarditis.5 passages
• COVID-19 surge threatens health in the Gaza strip.4 passages
• COVID-19 vaccination and HIV-1 acquisition - Authors' reply.2 passages
• COVID-19 vaccination and HIV-1 acquisition.1 passage
• COVID-19 vaccination for children aged 5-11 years.6 passages
• COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy.1 passage
• COVID-19 vaccination uptake for half a million non-EU migrants and refugees in England: a linked retrospective population-based cohort study.1 passage
• COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.46 passages
• COVID-19 vaccine efficacy data: solid enough to delay second dose?1 passage
• COVID-19 vaccine impact in Israel and a way out of the pandemic.7 passages
• COVID-19 vaccine research and the trouble with clinical equipoise.3 passages
• COVID-19 vaccine strategies must focus on severe disease and global equity.1 passage
• COVID-19 vaccines and women's security.5 passages
• COVID-19 vaccines for children in LMICs: another equity issue.7 passages
• COVID-19 vaccines for the European region: an unprecedented challenge.7 passages
• COVID-19, community trials, and inclusion.6 passages
• COVID-19, online shaming, and health-care professionals.10 passages
• COVID-19, structural racism, and migrant health in Canada.6 passages
• COVID-19: building a stronger Europe.5 passages
• COVID-19: forgetting a pandemic that is not over.2 passages
• COVID-19: learning as an interdependent world.5 passages
• COVID-19: the case for prosociality.5 passages
• COVID-19: the intersection of education and health.7 passages
• COVID-19: the next phase and beyond.6 passages
• COVID-19: the turning point for gender equality.10 passages
• COVID-19: where do we go from here?5 passages
• Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.52 passages
• Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.1 passage
• Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives.1 passage
• Call for a pan-European COVID-19 response must be comprehensive - Authors' reply.1 passage
• Call for emergency action to limit global temperature increases, restore biodiversity, and protect health.10 passages
• Call to action for a life course approach.1 passage
• Call to action: how can the US Ending the HIV Epidemic initiative succeed?1 passage
• Calling for benefit-risk evaluations of COVID-19 control measures.2 passages
• Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections.10 passages
• Calls for independent evaluation of ACT-A welcomed.4 passages
• Calls for transparency after SARS-CoV-2 origins report.5 passages
• Calls to restart testing for parasitic disease at US CDC.7 passages
• Cambodia ends controversial COVID-19 restrictions.4 passages
• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.1 passage
• Can COVID-19 help accelerate and transform the diagnostics agenda?9 passages
• Can India's COVID-19 emergency be fixed without politics?2 passages
• Can digital technologies improve health?5 passages
• Cancer vaccines and the future of immunotherapy.1 passage
• Cardiogenic shock.1 passage
• Cardiopulmonary resuscitation in special circumstances.1 passage
• Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.45 passages
• Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: a derivation and validation study.1 passage
• Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention.1 passage
• Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.50 passages
• Cataracts.1 passage
• Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature.1 passage
• Causal effects of later-eating rhythm on adiposity in children through the comparison of two cohorts in the UK and China: a cross-cohort study.1 passage
• Cause-specific mortality by county, race, and ethnicity in the USA, 2000-19: a systematic analysis of health disparities.1 passage
• Causes of and risk factors for postpartum haemorrhage: a systematic review and meta-analysis.1 passage
• Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management.1 passage
• Cell-free fetal DNA for genetic evaluation in Copenhagen Pregnancy Loss Study (COPL): a prospective cohort study.1 passage
• Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.1 passage
• Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial.1 passage
• Cerebral palsy.1 passage
• Cerebral venous sinus thrombosis after vaccination: the UK experience.6 passages
• Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study.51 passages
• Chagas disease.1 passage
• Challenges and opportunities for educating health professionals after the COVID-19 pandemic.104 passages
• Challenges and opportunities in developing integrated sexual and reproductive health programmes.1 passage
• Challenges and opportunities in interprofessional education and practice.8 passages
• Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.64 passages
• Changes in food and drink purchasing behaviour in England during the first 3 months of the COVID-19 pandemic: an interrupted time-series analysis.1 passage
• Changes in online food access during the COVID-19 pandemic and associations with deprivation: a longitudinal analysis.1 passage
• Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis.33 passages
• Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study.49 passages
• Characterising adults in Scotland who are not vaccinated against COVID-19.2 passages
• Characteristics and consequences of participatory research approaches in long-term care facilities for older adults: a meta-ethnography of qualitative studies.1 passage
• Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland.1 passage
• Charting a path to health for all at net-zero emissions.8 passages
• Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial.63 passages
• Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial.1 passage
• Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial.1 passage
• Child deprivation among Palestinian refugees in Lebanon and Palestinian refugees from Syria living in Lebanon: a cross-sectional analysis of co-occurrence of deprivation indicators.1 passage
• Childhood epilepsy.1 passage
• Childhood nephrotic syndrome.1 passage
• Children, intersectionality, and COVID-19.3 passages
• China needs a scientific long COVID recovery-support platform.3 passages
• China's response to COVID-19: a chance for collaboration.5 passages
• Cholera.1 passage
• Chris Butler: primary care research supremo.6 passages
• Chronic kidney disease.2 passages
• Chronic lymphocytic leukaemia.1 passage
• Chronic myeloid leukaemia.1 passage
• Chronic obstructive pulmonary disease.1 passage
• Chronic pain: an update on burden, best practices, and new advances.1 passage
• Chronic pancreatitis.1 passage
• Chronic suppurative otitis media.1 passage
• Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment.1 passage
• Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.1 passage
• Circadian rhythms and disorders of the timing of sleep.1 passage
• Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19.7 passages
• Classical Hodgkin lymphoma.1 passage
• Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.1 passage
• Clinical and bacteriological effectiveness of three different short-course antibiotic regimens and single-dose fosfomycin for uncomplicated lower urinary tract infections in women (SCOUT): a pragmatic, multicentre, open-label, randomised clinical trial.1 passage
• Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT): a pragmatic, superiority, open-label, randomised controlled trial.1 passage
• Clinical and pathological characteristics and hormone receptor status of women with breast cancer in the European Gaza Hospital: a retrospective chart-based review.1 passage
• Clinical aspects of snakebite envenoming and its treatment in low-resource settings.1 passage
• Clinical audit as a quality improvement tool in the Gaza Strip: an audit of audits.1 passage
• Clinical effectiveness and safety of time-lapse imaging systems for embryo incubation and selection in in-vitro fertilisation treatment (TILT): a multicentre, three-parallel-group, double-blind, randomised controlled trial.1 passage
• Clinical effectiveness of the psychological therapy Mental Health Intervention for Children with Epilepsy in addition to usual care compared with assessment-enhanced usual care alone: a multicentre, randomised controlled clinical trial in the UK.1 passage
• Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial.1 passage
• Clinical outcomes of uninterrupted embryo culture with or without time-lapse-based embryo selection versus interrupted standard culture (SelecTIMO): a three-armed, multicentre, double-blind, randomised controlled trial.1 passage
• Clinical presentation and epidemiological assessment of confirmed human mpox cases in DR Congo: a surveillance-based observational study.1 passage
• Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study.35 passages
• Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa.9 passages
• Clinician engineers-the time is now.2 passages
• Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis.1 passage
• Closing the global vaccine equity gap: equitably distributed manufacturing.9 passages
• Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial.1 passage
• Coeliac disease.1 passage
• Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial.1 passage
• Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST).1 passage
• Colombians protest over inequities and health care.5 passages
• Colorectal cancer.1 passage
• Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial.1 passage
• Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.1 passage
• Comics as anti-racist education and advocacy.15 passages
• Commercial determinants of health: future directions.1 passage
• Community engagement: learning from low-income countries.3 passages
• Community pandemic response: the importance of action led by communities and the public sector.9 passages
• Community-acquired bacterial meningitis.1 passage
• Community-acquired pneumonia.2 passages
• Community-based mentoring to reduce maternal and perinatal mortality in adolescent pregnancies in Sierra Leone (2YoungLives): a pilot cluster-randomised controlled trial.1 passage
• Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.38 passages
• Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.1 passage
• Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis.1 passage
• Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases.1 passage
• Comparing dedicated and designated approaches to integrating task-shared psychological interventions into chronic disease care in South Africa: a three-arm, cluster randomised, multicentre, open-label trial.1 passage
• Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.1 passage
• Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial.52 passages
• Comparison of inhalational methoxyflurane, intranasal fentanyl, and intravenous morphine for treatment of prehospital acute pain in Norway (PreMeFen): a randomised, non-inferiority, three-arm, phase 3 trial.1 passage
• Comparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trial.1 passage
• Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.1 passage
• Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial.1 passage
• Complement in human disease: approved and up-and-coming therapeutics.1 passage
• Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials.1 passage
• Complex post-traumatic stress disorder.1 passage
• Conceptualising commercial entities in public health: beyond unhealthy commodities and transnational corporations.1 passage
• Concerns about medical abuses against Uighurs in China.1 passage
• Concurrent outbreaks of mpox in Africa-an update.1 passage
• Confronting the consequences of racism, xenophobia, and discrimination on health and health-care systems.1 passage
• Confronting the evolution and expansion of anti-vaccine activism in the USA in the COVID-19 era.18 passages
• Congenital adrenal hyperplasia.1 passage
• Conservative management versus tonsillectomy in adults with recurrent acute tonsillitis in the UK (NATTINA): a multicentre, open-label, randomised controlled trial.1 passage
• Conservative versus liberal oxygenation targets in critically ill children (Oxy-PICU): a UK multicentre, open, parallel-group, randomised clinical trial.1 passage
• Consideration of factors associated with inequalities in interventions that support health-care professionals' interaction with patients to reduce inappropriate antimicrobial use: a systematic review.1 passage
• Contemporary medical, device, and surgical therapies for obesity in adults.1 passage
• Contemporary radiotherapy: present and future.1 passage
• Contemporary, non-invasive imaging diagnosis of chronic coronary artery disease.1 passage
• Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization.48 passages
• Controversy surrounds Merkel's new lockdown powers.5 passages
• Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.45 passages
• Convalescent plasma in patients hospitalised with COVID-19.4 passages
• Cooling cities through urban green infrastructure: a health impact assessment of European cities.1 passage
• CoronaVac efficacy data from Turkey.1 passage
• CoronaVac: more data for regulators and policy makers.8 passages
• Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.1 passage
• Coronary microvascular dysfunction and cardiovascular outcomes (Multicenter FLOW-CMD Registry): a prospective, multicentre cohort study in South Korea.1 passage
• Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.1 passage
• Correlates of protection from SARS-CoV-2 infection.5 passages
• Counting the global COVID-19 dead.6 passages
• Countries split from EU on COVID-19 vaccines.5 passages
• Critically ill COVID-19 patients in Africa: it is time for quality registry data.1 passage
• Crohn's disease.1 passage
• Cumulative incidence of advanced breast cancer in women aged 40-49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis.1 passage
• Current and future status of JAK inhibitors.1 passage
• Current best practice for bladder cancer: a narrative review of diagnostics and treatments.1 passage
• Current concepts in coronary artery revascularisation.1 passage
• Current treatment for symptomatic uterine fibroids: available evidence and therapeutic dilemmas.1 passage
• Cushing's syndrome.1 passage
• Cutaneous melanoma.1 passage
• Cystic fibrosis.1 passage
• DNA vaccines join the fight against COVID-19.1 passage
• Daily antigen testing to reduce disruption when schools return.6 passages
• Daily experiences and strategies for psychological survival during the 2014 assaults in Gaza: a retrospective analysis of chronological diaries.1 passage
• Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial.58 passages
• Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial.1 passage
• Data-driven policies needed to turn the tide on diabetes.8 passages
• De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.1 passage
• Deaths of despair in England: an observational study of local authority mortality data.1 passage
• Deaths potentially averted by small changes in physical activity and sedentary time: an individual participant data meta-analysis of prospective cohort studies.1 passage
• Decentralised elements in clinical trials: recommendations from the European Medicines Regulatory Network.4 passages
• Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial.1 passage
• Decoupling of omicron variant infections and severe COVID-19.4 passages
• Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.1 passage
• Deferred cord clamping, cord milking, and immediate cord clamping at preterm birth: a systematic review and individual participant data meta-analysis.1 passage
• Defining and conceptualising the commercial determinants of health.1 passage
• Defining collaborative surveillance to improve decision making for public health emergencies and beyond.1 passage
• Delayed COVID-19 vaccine roll-out in Japan.1 passage
• Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?5 passages
• Delivering health and nutrition interventions for women and children in different conflict contexts: a framework for decision making on what, when, and how.1 passage
• Delivering health interventions to women, children, and adolescents in conflict settings: what have we learned from ten country case studies?1 passage
• Dengue.1 passage
• Department of Error.45 passages
• Depression and anxiety disorders during the COVID-19 pandemic: knowns and unknowns.4 passages
• Depression and anxiety during COVID-19 - Authors' reply.3 passages
• Depression in young people.1 passage
• Depression.1 passage
• Determinants of lipid clinic referral and attendance in a multi-ethnic adult population in south London: a cross-sectional study.1 passage
• Developing and piloting an intervention to reduce colposcopy non-attendance and corresponding inequalities: a mixed-methods study.1 passage
• Development of a framework for action to advocate for a coherent prevention policy for tobacco, alcohol, and foods high in fats, salt, or sugar: a mixed-methods approach.1 passage
• Development of a targeted client communication intervention for pregnant and post-partum women: a descriptive study.1 passage
• Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.1 passage
• Diagnosis and management of ANCA-associated vasculitis.1 passage
• Diagnosis of non-consensus transient ischaemic attacks with focal, negative, and non-progressive symptoms: population-based validation by investigation and prognosis.54 passages
• Diagnostics for COVID-19: moving from pandemic response to control.64 passages
• Did anonymity in self-administered questionnaires improve disclosure of sensitive information during the 2022 mpox outbreak in England? An observational study.1 passage
• Differences in the impact of the COVID-19 pandemic in the long-term trajectories of life satisfaction by sex in the UK: a prospective cohort study.1 passage
• Differentiating mortality risk of individual infants and children to improve survival: opportunity for impact.1 passage
• Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches.1 passage
• Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.1 passage
• Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.1 passage
• Disease burden attributable to intimate partner violence against females and sexual violence against children in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.81 passages
• Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia?1 passage
• Disease surveillance for the COVID-19 era: time for bold changes.7 passages
• Disparities in wellbeing in the USA by race and ethnicity, age, sex, and location, 2008-21: an analysis using the Human Development Index.1 passage
• Disrespectful language about patients with long COVID.2 passages
• Disrupted care in Papua New Guinea: the harms of COVID-19.10 passages
• Disruptions to childhood immunisation due to the COVID-19 pandemic.6 passages
• Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.11 passages
• Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.1 passage
• Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.1 passage
• Dose-response of accelerometer-measured physical activity, step count, and cancer risk in the UK Biobank: a prospective cohort analysis.1 passage
• Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.1 passage
• Drug therapy for osteoporosis in older adults.1 passage
• Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial.1 passage
• Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S).1 passage
• Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial.1 passage
• Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.1 passage
• Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.1 passage
• Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial.1 passage
• Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.32 passages
• Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.52 passages
• Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.1 passage
• Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.1 passage
• ECMO in COVID-19: do not blame the tool.5 passages
• ECMO support for COVID-19: a balancing act - Authors' reply.3 passages
• ECMO support for COVID-19: a balancing act.1 passage
• Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.47 passages
• Early childhood lower respiratory tract infection and premature adult death from respiratory disease in Great Britain: a national birth cohort study.1 passage
• Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.1 passage
• Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial.1 passage
• Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.6 passages
• Early versus delayed weight-bearing following operatively treated ankle fracture (WAX): a non-inferiority, multicentre, randomised controlled trial.1 passage
• Early-onset type 2 diabetes: the next major diabetes transition.1 passage
• Easy in, tough out: the dam of health-care racism.4 passages
• Education and mental health: good reasons to vaccinate children.1 passage
• Effect of a spatial repellent on malaria incidence in an area of western Kenya characterised by high malaria transmission, insecticide resistance, and universal coverage of insecticide treated nets (part of the AEGIS Consortium): a cluster-randomised, controlled trial.1 passage
• Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.1 passage
• Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial.1 passage
• Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials.1 passage
• Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.1 passage
• Effect of high versus standard protein provision on functional recovery in people with critical illness (PRECISe): an investigator-initiated, double-blinded, multicentre, parallel-group, randomised controlled trial in Belgium and the Netherlands.1 passage
• Effect of hypertension on pregnancy outcomes at UNRWA health centres in Gaza governorates: a comparative study.1 passage
• Effect of infusion set replacement intervals on catheter-related bloodstream infections (RSVP): a randomised, controlled, equivalence (central venous access device)-non-inferiority (peripheral arterial catheter) trial.1 passage
• Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial.1 passage
• Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial.56 passages
• Effect of nurse-supported care on pain management in women undergoing caesarean delivery: a comparative study.1 passage
• Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.9 passages
• Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.1 passage
• Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.50 passages
• Effect of the COVID-19 pandemic on incidence of long-term conditions in Welsh residents: a population linkage study.1 passage
• Effect of trade unions on the mental health of UK workers before and during the COVID-19 pandemic: a longitudinal analysis using Understanding Society data.1 passage
• Effective post-pandemic governance must focus on shared challenges.10 passages
• Effective supply chain surveillance for PPE.1 passage
• Effectiveness and cost-effectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised trial.53 passages
• Effectiveness and cost-effectiveness of an individualised, progressive walking and education intervention for the prevention of low back pain recurrence in Australia (WalkBack): a randomised controlled trial.1 passage
• Effectiveness and cost-effectiveness of reactive, targeted indoor residual spraying for malaria control in low-transmission settings: a cluster-randomised, non-inferiority trial in South Africa.51 passages
• Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.35 passages
• Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial.1 passage
• Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.1 passage
• Effectiveness of a symptom-clinic intervention delivered by general practitioners with an extended role for people with multiple and persistent physical symptoms in England: the Multiple Symptoms Study 3 pragmatic, multicentre, parallel-group, individually randomised controlled trial.1 passage
• Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.33 passages
• Effectiveness of ferritin-guided donation intervals in whole-blood donors in the Netherlands (FIND'EM): a stepped-wedge cluster-randomised trial.1 passage
• Effectiveness of handwashing with soap for preventing acute respiratory infections in low-income and middle-income countries: a systematic review and meta-analysis.1 passage
• Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis.1 passage
• Effectiveness of interactive workshops to raise awareness of the neurological harms associated with nitrous oxide use: a cross-sectional study.1 passage
• Effectiveness of interventions for improving physical activity level in working-age people (aged 18-60 years) with type 2 diabetes: a systematic review and meta-analysis.1 passage
• Effectiveness of interventions to improve drinking water, sanitation, and handwashing with soap on risk of diarrhoeal disease in children in low-income and middle-income settings: a systematic review and meta-analysis.42 passages
• Effectiveness of kangaroo mother care before clinical stabilisation versus standard care among neonates at five hospitals in Uganda (OMWaNA): a parallel-group, individually randomised controlled trial and economic evaluation.39 passages
• Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.40 passages
• Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.43 passages
• Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.51 passages
• Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA.19 passages
• Effectiveness, cost-effectiveness, and positive externalities of integrated chronic care for adults with major depressive disorder in Malawi (IC3D): a stepped-wedge, cluster-randomised, controlled trial.1 passage
• Effects of change in hospital treatment payment policy for Palestinian refugees in Lebanon: a health economics analysis.1 passage
• Effects of early-life poverty on health and human capital in children and adolescents: analyses of national surveys and birth cohort studies in LMICs.1 passage
• Effects of handwashing with soap on acute respiratory infections in low-resource settings: challenges and ways forward.5 passages
• Effects of nurse-to-patient ratio legislation on nurse staffing and patient mortality, readmissions, and length of stay: a prospective study in a panel of hospitals.46 passages
• Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial.1 passage
• Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials.1 passage
• Effects of race and ethnicity on perinatal outcomes in high-income and upper-middle-income countries: an individual participant data meta-analysis of 2 198 655 pregnancies.1 passage
• Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort.52 passages
• Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.1 passage
• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.1 passage
• Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.1 passage
• Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.1 passage
• Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.1 passage
• Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.1 passage
• Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China.1 passage
• Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.48 passages
• Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.1 passage
• Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.1 passage
• Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial.1 passage
• Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.1 passage
• Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.1 passage
• Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.1 passage
• Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.1 passage
• Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.1 passage
• Efficacy and safety of emodepside compared with albendazole in adolescents and adults with hookworm infection in Pemba Island, Tanzania: a double-blind, superiority, phase 2b, randomised controlled trial.1 passage
• Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.1 passage
• Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.1 passage
• Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.1 passage
• Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.1 passage
• Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study.1 passage
• Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.1 passage
• Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.1 passage
• Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.1 passage
• Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.1 passage
• Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial.1 passage
• Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.1 passage
• Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial.1 passage
• Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial.1 passage
• Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.1 passage
• Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.1 passage
• Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.1 passage
• Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.1 passage
• Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.1 passage
• Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.1 passage
• Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.1 passage
• Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.1 passage
• Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study.1 passage
• Efficacy and safety of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy versus Roux-en-Y gastric bypass in France (SADISLEEVE): results of a randomised, open-label, superiority trial at 2 years of follow-up.1 passage
• Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.1 passage
• Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.1 passage
• Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.1 passage
• Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.1 passage
• Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.1 passage
• Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials.1 passage
• Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.1 passage
• Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.57 passages
• Efficacy of a culturally adapted, cognitive behavioural therapy-based intervention for postnatal depression in British south Asian women (ROSHNI-2): a multicentre, randomised controlled trial.1 passage
• Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.54 passages
• Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine.1 passage
• Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.1 passage
• Efficacy of pyriproxyfen-pyrethroid long-lasting insecticidal nets (LLINs) and chlorfenapyr-pyrethroid LLINs compared with pyrethroid-only LLINs for malaria control in Benin: a cluster-randomised, superiority trial.1 passage
• Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.50 passages
• Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.48 passages
• Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.1 passage
• Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.1 passage
• Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.1 passage
• Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.47 passages
• Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.56 passages
• Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.1 passage
• Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries.49 passages
• Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial.1 passage
• Eliminating postnatal HIV transmission in high incidence areas: need for complementary biomedical interventions.1 passage
• Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.1 passage
• Emergency response of the UNRWA health programme to Great March of Return injuries: a descriptive analytic study in Gaza.1 passage
• Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.1 passage
• Enabling health and maintaining independence for older people at home (HomeHealth trial): a multicentre randomised controlled trial.1 passage
• Encephalitis.1 passage
• Ending HIV in the USA: integrating social determinants of health - Authors' reply.1 passage
• Endometrial cancer.1 passage
• Endometriosis is a chronic systemic disease: clinical challenges and novel innovations.1 passage
• Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial.1 passage
• Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trial.1 passage
• Endovascular management of acute stroke.1 passage
• Endovascular therapy for acute vertebrobasilar occlusion (VERITAS): a systematic review and individual patient data meta-analysis.1 passage
• Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial.1 passage
• Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication.1 passage
• Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial.1 passage
• Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial.1 passage
• Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial.1 passage
• Engagement of individuals aged 14-25 years with a digital mental health service during the COVID-19 pandemic in the UK: a cohort study of service usage data.1 passage
• Enhancing anti-tumour efficacy with immunotherapy combinations.1 passage
• Enhancing the quality of maternal and neonatal care by the Safe Childbirth Project in Al Shifa Hospital, Gaza occupied Palestinian territory (oPt): a descriptive retrospective study.1 passage
• Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.1 passage
• Ensure Palestinians have access to COVID-19 vaccines.3 passages
• Ensuring progress on sustainable access to effective antibiotics at the 2024 UN General Assembly: a target-based approach.1 passage
• Enteric (typhoid and paratyphoid) fever.1 passage
• Envisioning environmental equity: climate change, health, and racial justice.84 passages
• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.1 passage
• Epidemiological and clinical features of mpox during the clade Ib outbreak in South Kivu, Democratic Republic of the Congo: a prospective cohort study.1 passage
• Epidemiological and demographic trends and projections in global health from 1970 to 2050: a descriptive analysis from the third Lancet Commission on Investing in Health, Global Health 2050.40 passages
• Epidemiology and management of gestational diabetes.1 passage
• Epidemiology and phylogenomic characterisation of two distinct mpox outbreaks in Kinshasa, DR Congo, involving a new subclade Ia lineage: a retrospective, observational study.1 passage
• Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses.1 passage
• Epidemiology, not geopolitics, should guide COVID-19 vaccine donations.9 passages
• Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21.72 passages
• Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study.50 passages
• Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.85 passages
• Estimating the cause-specific relative risks of non-optimal temperature on daily mortality: a two-part modelling approach applied to the Global Burden of Disease Study.38 passages
• Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data.38 passages
• Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: a systematic review and meta-analysis.43 passages
• Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.44 passages
• Estimating the potential malaria morbidity and mortality avertable by the US President's Malaria Initiative in 2025: a geospatial modelling analysis.1 passage
• Estimating total spending by source of funding on routine and supplementary immunisation activities in low-income and middle-income countries, 2000-17: a financial modelling study.65 passages
• Estimation of HbA1c after weight loss using a beta-regression for an economic evaluation of a behavioural weight management programme from the GLoW trial: a methodological study.1 passage
• Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform.48 passages
• Ethnic disparities in COVID-19: increased risk of infection or severe disease?1 passage
• Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.1 passage
• Evaluating COVID-19 vaccines in the real world.1 passage
• Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials.1 passage
• Evaluating the Change4Life Food Scanner app in reducing children's sugar intake: a randomised pilot and feasibility study.1 passage
• Evaluating the effect of minimum unit pricing for unit of alcohol on road traffic accidents in Scotland: a controlled interrupted time-series study.1 passage
• Evaluating the effectiveness of community health worker interventions on glycaemic control in type 2 diabetes: a systematic review and meta-analysis.1 passage
• Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study.1 passage
• Evaluating the impact of alcohol minimum unit pricing on deaths and hospitalisations in Scotland: a controlled interrupted time series study.42 passages
• Evaluating the impact of minimum unit pricing for alcohol in Scotland: a theory-based synthesis of the evidence.1 passage
• Evaluating the impact of two decades of USAID interventions and projecting the effects of defunding on mortality up to 2030: a retrospective impact evaluation and forecasting analysis.55 passages
• Evaluation of Dementia Actif, a dementia-friendly exercise and wellbeing programme: mixed-methods study.1 passage
• Evaluation of community outreach feasibility programmes on improving cancer-related, preventive, health behaviour.1 passage
• Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study.1 passage
• Evaluation of mass media campaign of early cancer diagnosis, targeting older adults in Northern Ireland: a cross-sectional study.1 passage
• Evaluation of the impact of letters to GP practices to promote asthma prescription uptake in school-age children during summer (TRAINS study): a pragmatic cluster-randomised controlled trial.1 passage
• Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial.48 passages
• Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.44 passages
• Evidence of human-to-dog transmission of monkeypox virus.6 passages
• Evidence-based antenatal interventions to reduce the incidence of small vulnerable newborns and their associated poor outcomes.1 passage
• Evolutionary consequences of delaying intervention for monkeypox.1 passage
• Excess COVID-19 mortality among critically ill patients in Africa.6 passages
• Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.1 passage
• Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.1 passage
• Expanding the concept of safety in antenatal care provision.5 passages
• Expedited transfer to a cardiac arrest centre for non-ST-elevation out-of-hospital cardiac arrest (ARREST): a UK prospective, multicentre, parallel, randomised clinical trial.43 passages
• Experience of homelessness during the COVID-19 pandemic in Tower Hamlets, London: a health needs assessment.1 passage
• Experiences of menopause in the Welsh NHS workplace: a focus group study.1 passage
• Experts criticise India's complacency over COVID-19.9 passages
• Explaining differential socioeconomic effects in population health interventions: development and application of a new tool to classify intervention agentic demand.1 passage
• Exploring substance misuse in a prison in Wales: a cross-sectional analysis.1 passage
• Exploring the experiences of junior doctors who were shielding during the COVID-19 pandemic: a qualitative study of semi-structured interviews.1 passage
• Extended optical treatment versus early patching with an intensive patching regimen in children with amblyopia in Europe (EuPatch): a multicentre, randomised controlled trial.1 passage
• Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial.1 passage
• Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.1 passage
• Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry.44 passages
• Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.1 passage
• Factors affecting the delivery of community-based salon interventions to prevent cardiovascular disease and breast cancer among ethnically diverse women in South London: a concept-mapping approach.1 passage
• Factors associated with multimorbidity in England: an analysis of the English Longitudinal Study of Ageing.1 passage
• Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study.1 passage
• Fatal police violence by race and state in the USA, 1980-2019: a network meta-regression.58 passages
• Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study.1 passage
• Feasibility of interrupting the transmission of soil-transmitted helminths: the DeWorm3 community cluster-randomised controlled trial in Benin, India, and Malawi.1 passage
• Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.55 passages
• Ferric carboxymaltose versus standard-of-care oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised controlled trial.67 passages
• Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination.1 passage
• Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.1 passage
• Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.1 passage
• Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.60 passages
• Financing the future of WHO.1 passage
• Finding hope in two pandemics.9 passages
• First dose of misoprostol administration at home or in hospital for medical abortion between 12-22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial.1 passage
• First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.1 passage
• First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.1 passage
• First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.1 passage
• Five priorities for universal COVID-19 vaccination.7 passages
• Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.1 passage
• Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.1 passage
• Fixing US public health infrastructure for 1% of annual military budget.2 passages
• Flexible resources and experiences of racism among a multi-ethnic adolescent population in Aotearoa, New Zealand: an intersectional analysis of health and socioeconomic inequities using survey data.1 passage
• Food choice in transition: adolescent autonomy, agency, and the food environment.1 passage
• Food insecurity among pregnant women living in high-income countries: a systematic review.1 passage
• Food insecurity and diet quality in households accessing food membership clubs in Wessex: a mixed-methods study.1 passage
• Food insecurity in the context of conflict: analysis of survey data in the occupied Palestinian territory.1 passage
• Fragmented health systems in COVID-19: rectifying the misalignment between global health security and universal health coverage.25 passages
• Framing and the formation of global health priorities.1 passage
• Free licensing of vaccines to end the COVID-19 crisis.3 passages
• From routine data collection to policy design: sex and gender both matter in COVID-19.7 passages
• Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.1 passage
• Functioning of the International Health Regulations during the COVID-19 pandemic.20 passages
• Future scenarios for the COVID-19 pandemic.6 passages
• Gagandeep Kang: helping to shape a healthier India.6 passages
• Gait retraining to reduce falls: an experimental study toward scalable and personalised use in the home.1 passage
• Gastric cancer.1 passage
• Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study.1 passage
• Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study.1 passage
• General and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7·5 million participants.27 passages
• Genetic sequencing analysis of monkeypox virus clade I in Republic of the Congo: a cross-sectional, descriptive study.1 passage
• Genomic sequencing in pandemics.5 passages
• Germany's role in global health at a critical juncture.1 passage
• Gestational age recorded at delivery versus estimations using antenatal care data from the Electronic Maternal and Child Health Registry in the West Bank: a comparative analysis.1 passage
• Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study.1 passage
• Gillian Hanson: UK innovator in intensive care medicine.5 passages
• Glaucoma: now and beyond.1 passage
• Global COVID-19 vaccine roll-out: time to randomise vaccine allocation?1 passage
• Global Fund secures $14·3 billion from donors.11 passages
• Global HIV efforts need to focus on key populations in LMICs.1 passage
• Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.198 passages
• Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.159 passages
• Global and regional governance of One Health and implications for global health security.1 passage
• Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.129 passages
• Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.124 passages
• Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.180 passages
• Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.112 passages
• Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.81 passages
• Global burden of cancer in children and adolescents aged 0-19 years, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.1 passage
• Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data.1 passage
• Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019.50 passages
• Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.133 passages
• Global health 2050: the path to halving premature death by mid-century.296 passages
• Global health and its discontents.1 passage
• Global health diplomacy-reconstructing power and governance.47 passages
• Global heating: an urgent call for action to protect health.5 passages
• Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.118 passages
• Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study.50 passages
• Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.51 passages
• Global pandemic perspectives: public health, mental health, and lessons for the future.22 passages
• Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).1 passage
• Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic.47 passages
• Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.7 passages
• Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories.1 passage
• Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.56 passages
• Global youth advocating for COVID-19 vaccines for all.5 passages
• Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.1 passage
• Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.77 passages
• Global, regional, and national burden of household air pollution, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.52 passages
• Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.36 passages
• Global, regional, and national estimates and trends in stillbirths from 2000 to 2019: a systematic assessment.58 passages
• Global, regional, and national mortality among young people aged 10-24 years, 1950-2019: a systematic analysis for the Global Burden of Disease Study 2019.63 passages
• Global, regional, and national mortality burden attributable to air pollution from landscape fires: a health impact assessment study.1 passage
• Global, regional, and national prevalence estimates of physical or sexual, or both, intimate partner violence against women in 2018.42 passages
• Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.60 passages
• Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.83 passages
• Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019.88 passages
• Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021.135 passages
• Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.86 passages
• Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.83 passages
• Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.1 passage
• Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.1 passage
• Goal setting as part of a holistic intervention to promote independence in older people with mild frailty: a process evaluation alongside a randomised controlled trial.1 passage
• Gout.1 passage
• Governance of health emergencies.2 passages
• Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability.36 passages
• Governments policy measures to address obesity among adults: a scoping review of the global evidence.1 passage
• Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report.1 passage
• Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.1 passage
• Guidelines for pregnant individuals with monkeypox virus exposure.5 passages
• Guidelines should not pool evidence from uncomplicated and severe COVID-19.2 passages
• Guillain-Barré syndrome.1 passage
• Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.1 passage
• HERA: a new era for health emergency preparedness in Europe?1 passage
• HIV and women in the USA: what we know and where to go from here.1 passage
• HIV epidemiology, prevention, treatment, and implementation strategies for public health.1 passage
• Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials.1 passage
• Haemochromatosis.1 passage
• Haemodiafiltration versus haemodialysis for kidney failure: an individual patient data meta-analysis of randomised controlled trials.1 passage
• Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial.1 passage
• Haemolytic uraemic syndrome.1 passage
• Haemophilia.1 passage
• Haiti's health woes intensify.5 passages
• Haiti's kidney transplantation unit.4 passages
• Halving premature death and improving quality of life at all ages: cross-country analyses of past trends and future directions.44 passages
• Hand eczema.1 passage
• Head and neck cancer.1 passage
• Health and development from preconception to 20 years of age and human capital.1 passage
• Health and inclusive labour force participation.1 passage
• Health as activism: rethinking social medicine in India.10 passages
• Health attacks and protection strategies during Gaza's Great March of Return: a mixed methods study using data from WHO's Surveillance System for Attacks on Healthcare.1 passage
• Health care in the USA: money has become the mission.1 passage
• Health experts slam Bolsonaro's vaccine comments.5 passages
• Health experts welcome Brazil COVID-19 inquiry findings.11 passages
• Health for all requires commitment to healthy ageing.2 passages
• Health inequalities, ethnic minorities and COVID19: interactive theatre workshop drawing on a qualitative interview study.1 passage
• Health leaders criticise limited ACT-A review.10 passages
• Health system performance in Iran: a systematic analysis for the Global Burden of Disease Study 2019.70 passages
• Health systems neglected by COVID-19 donors.7 passages
• Health, economic, and equity consequences of future tobacco control policies in England: a microsimulation study.1 passage
• Health-care workforce implications of the Dobbs v Jackson Women's Health Organization decision.1 passage
• Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial.1 passage
• Hearing loss prevalence and years lived with disability, 1990-2019: findings from the Global Burden of Disease Study 2019.49 passages
• Heart failure with preserved ejection fraction: everything the clinician needs to know.1 passage
• Heart failure with reduced ejection fraction.1 passage
• Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial.1 passage
• Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial.1 passage
• Hepatitis B.1 passage
• Hepatitis C.1 passage
• Hepatocellular carcinoma.1 passage
• Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.8 passages
• Heterologous vaccine regimens against COVID-19.5 passages
• Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.42 passages
• Hidradenitis suppurativa.1 passage
• High-dose budesonide for early COVID-19 - Authors' reply.1 passage
• High-dose budesonide for early COVID-19.1 passage
• High-dose dual-antibiotic loaded cement for hip hemiarthroplasty in the UK (WHiTE 8): a randomised controlled trial.1 passage
• High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19.1 passage
• Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.47 passages
• Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia?1 passage
• Histiocytosis.1 passage
• Historical evidence to inform COVID-19 vaccine mandates.3 passages
• Holding powerful corporations accountable for their health impacts: are corporate rankings effective?1 passage
• Home-based monitoring of ovulation to time frozen embryo transfers in the Netherlands (Antarctica-2): an open-label, nationwide, randomised, non-inferiority trial.1 passage
• Hope for nutrition summit as global hunger spikes.9 passages
• Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis.1 passage
• Hospital admissions due to COVID-19 in Scotland after one dose of vaccine.6 passages
• Hospital admissions for physical health and psychosocial adversity among people experiencing homelessness in England: a population-based retrospective cross-sectional study.1 passage
• Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave.6 passages
• Host-targeting oral antiviral drugs to prevent pandemics.6 passages
• Hot weather and heat extremes: health risks.1 passage
• Household food insecurity and child health outcomes: a rapid review of mechanisms and associations.1 passage
• How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic.75 passages
• How can engagement with political science and international relations for health be improved?6 passages
• How did female survivors of abuse use the arts to support their mental health and wellbeing during the COVID-19 pandemic? A qualitative exploration of their views.1 passage
• How did living in temporary accommodation during the COVID-19 pandemic affect children younger than 5 years' access to health care and health outcomes? A qualitative study of key professionals in a socially and ethnically diverse and deprived area of London.1 passage
• How does the environment in and around the home affect social care and health outcomes for older people? A national longitudinal dynamic cohort study.1 passage
• How prepared is the world? Identifying weaknesses in existing assessment frameworks for global health security through a One Health approach.1 passage
• How to fix democracy to fix health care.2 passages
• How to interpret the total number of SARS-CoV-2 infections.5 passages
• Human African trypanosomiasis.1 passage
• Human flourishing in a health-creating society.9 passages
• Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series.48 passages
• Human rights and fair access to COVID-19 vaccines: the International AIDS Society-Lancet Commission on Health and Human Rights.1 passage
• Human rights and the COVID-19 pandemic: a retrospective and prospective analysis.85 passages
• Human schistosomiasis.1 passage
• Human security and universal health coverage: Japan's vision for the G7 Hiroshima Summit.8 passages
• Hyperemesis gravidarum.1 passage
• Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.1 passage
• Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.53 passages
• Hyperthyroidism.1 passage
• Hypertrophic cardiomyopathy: a practical approach to guideline directed management.1 passage
• Hypopituitarism.1 passage
• Hypothermic oxygenated perfusion of the donor heart in heart transplantation: the short-term outcome from a randomised, controlled, open-label, multicentre clinical trial.1 passage
• Hypothyroidism.1 passage
• IL-23 inhibition for chronic inflammatory disease.1 passage
• IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.1 passage
• IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.1 passage
• Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.53 passages
• Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.1 passage
• Identification of tax options for high fat, sugar, salt foods for the HEALTHEI Project: a mixed-methods study.1 passage
• Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study.1 passage
• Imagining alternative paths for WHO 75 years in.16 passages
• Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION-STEMI): a multicentre, non-inferiority, open-label, randomised trial.1 passage
• Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial.1 passage
• Immobilisation of torus fractures of the wrist in children (FORCE): a randomised controlled equivalence trial in the UK.1 passage
• Immune checkpoint inhibitors in melanoma.1 passage
• Immune response after pig-to-human kidney xenotransplantation: a multimodal phenotyping study.1 passage
• Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.44 passages
• Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial.1 passage
• Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.42 passages
• Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.1 passage
• Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial.1 passage
• Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients.1 passage
• Impact and cost-effectiveness of a lethal house lure against malaria transmission in central Côte d'Ivoire: a two-arm, cluster-randomised controlled trial.60 passages
• Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.45 passages
• Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study.1 passage
• Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.51 passages
• Impact of discontinuing oxytocin in active labour on neonatal morbidity: an open-label, multicentre, randomised trial.1 passage
• Impact of introducing RTS,S/AS01E malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme.1 passage
• Impact of long COVID-19 on work: a co-produced survey.1 passage
• Impact of messaging informed by behavioural science on uptake of targeted lung health checks: a service evaluation.1 passage
• Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review.1 passage
• Impact of the temporary suspension of the Bowel Screening Wales programme on inequalities during the COVID-19 pandemic: a retrospective register-based study.1 passage
• Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial.1 passage
• Implementing behavioural science informed letter interventions to increase COVID-19 vaccination uptake in uncontactable London residents: a difference-in-difference study in London, UK.1 passage
• Implementing the commitments of the World Health Assembly kidney health resolution: a key opportunity to improve health for millions.1 passage
• Improved hypertension care requires measurement and management in health facilities, not mass screening.1 passage
• Improved models of care for cancer survivors.56 passages
• Improvement in trauma care for road traffic injuries: an assessment of the effect on mortality in low-income and middle-income countries.1 passage
• Improving health and social systems for all children in LMICs: structural innovations to deliver high-quality services.1 passage
• Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact.1 passage
• Improving lung health in low-income and middle-income countries: from challenges to solutions.1 passage
• Improving prisoner health for stronger public health.7 passages
• Improving the quality of written communication at patient discharge: triangulation of qualitative analyses and intervention co-design.1 passage
• In-hospital complications associated with COVID-19.6 passages
• Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19.5 passages
• Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.1 passage
• Inclusion of women who are pregnant, lactating, or of reproductive potential in clinical trials: health, ethical, and regulatory considerations.1 passage
• Increasing children's global access to COVID-19 vaccines.6 passages
• Increasing compliance with international pandemic law: international relations and new global health agreements.1 passage
• Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest London.2 passages
• India begins COVID-19 vaccination amid trial allegations.5 passages
• India's COVID-19 crisis: a call for international action.19 passages
• India's COVID-19 emergency.5 passages
• India's COVID-19 emergency: overarching conclusions belie facts.2 passages
• India's COVID-19 response: science first.4 passages
• India's ascendancy: leadership demands integrity.7 passages
• India's pain: beyond COVID-19 case numbers and mortality rates.3 passages
• India's problem of data and deaths.3 passages
• India's resurgence of COVID-19: urgent actions needed.9 passages
• Indigenous health-care sovereignty defines resilience to the COVID-19 pandemic.1 passage
• Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.1 passage
• Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial.1 passage
• Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial.1 passage
• Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.42 passages
• Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.1 passage
• Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial.1 passage
• Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.1 passage
• Infective endocarditis.1 passage
• Infectivity of asymptomatic versus symptomatic COVID-19.5 passages
• Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.1 passage
• Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study.1 passage
• Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.1 passage
• Influenza.57 passages
• Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.49 passages
• Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.1 passage
• Innovation for infection prevention and control-revisiting Pasteur's vision.41 passages
• Innovations in the biomedical prevention, diagnosis, and service delivery of HIV and other sexually transmitted infections.1 passage
• Insomnia.1 passage
• Institutional imperatives for the advancement of women in medicine and science through the COVID-19 pandemic.7 passages
• Insurance coverage and financing landscape for HIV treatment and prevention in the USA.1 passage
• Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial.1 passage
• Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.1 passage
• Integrated respiratory surveillance after the COVID-19 pandemic.2 passages
• Integration of mental health and psychosocial support services into primary health care in Gaza: a cross-sectional evaluation.1 passage
• Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.1 passage
• Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.49 passages
• Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial.1 passage
• International cooperation to end the COVID-19 pandemic.2 passages
• International evidence on lived experiences of trauma during homelessness and effects on mental health including substance use: a co-produced qualitative systematic review.1 passage
• International law reform for One Health notifications.1 passage
• Intersectional insights into racism and health: not just a question of identity.1 passage
• Intersectionality and developing evidence-based policy.1 passage
• Interstitial lung diseases.1 passage
• Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy trial.1 passage
• Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial.1 passage
• Interventions to address global inequity in diabetes: international progress.1 passage
• Interventions to improve access to primary care for inclusion health groups in England: a scoping review.1 passage
• Interventions to improve oral health and related health behaviours of substance use, smoking, and diet in people with severe and multiple disadvantage: a systematic review of effectiveness and cost-effectiveness.1 passage
• Intracytoplasmic sperm injection versus conventional in-vitro fertilisation for couples with infertility with non-severe male factor: a multicentre, open-label, randomised controlled trial.1 passage
• Intracytoplasmic sperm injection versus conventional in-vitro fertilisation in couples with infertility in whom the male partner has normal total sperm count and motility: an open-label, randomised controlled trial.1 passage
• Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study.1 passage
• Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.1 passage
• Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial.1 passage
• Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.1 passage
• Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.1 passage
• Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.1 passage
• Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.1 passage
• Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms (FUTURE) in the UK: a multicentre, superiority, parallel, open-label, randomised controlled trial.1 passage
• Investigating monkeypox.10 passages
• Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.1 passage
• Iran's burden of disease and burden of data collection.1 passage
• Iron deficiency.1 passage
• Is NHS Test and Trace exacerbating COVID-19 inequalities?4 passages
• Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.1 passage
• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.1 passage
• Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.1 passage
• Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.1 passage
• Jamal Rifi: family doctor building bridges in the community.5 passages
• Japan's role for a peaceful and healthier world.2 passages
• Japanese medical workers' sacrifice for universal health coverage.2 passages
• KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.1 passage
• Knowledge and attitude of Palestinian women to contraceptives: a cross-sectional study.1 passage
• LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial.1 passage
• LGBTQ youth mental health during COVID-19: unmet needs in public health and policy.6 passages
• LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.1 passage
• Lancet Countdown on health and climate change in Africa: an international collaboration for locally led research and action.1 passage
• Large-vessel vasculitis.1 passage
• Learning from crises.2 passages
• Learning from crisis: building resilient systems to combat future pandemics.32 passages
• Learning from serosurveillance for SARS-CoV-2 to inform pandemic preparedness and response.7 passages
• Legal challenges threaten Biden's COVID-19 vaccine rule.9 passages
• Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access.48 passages
• Leprosy.1 passage
• Lessons from the Gateway programme, aimed at improving health and life chances for young people committing low-level offences: a qualitative evaluation.1 passage
• Lessons from the NHS for UHC and health security.5 passages
• Lessons learned from COVID-19 to stop future pandemics.2 passages
• Lessons learned from co-production in public health research: the MAMAH case study involving underserved migrant mothers in the UK.1 passage
• Life conditions and quality of life of Palestinians living in the Biddu Enclave: a qualitative study.1 passage
• Life expectancy by county, race, and ethnicity in the USA, 2000-19: a systematic analysis of health disparities.1 passage
• Life expectancy losses in the Gaza Strip during the period October, 2023, to September, 2024.1 passage
• Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.1 passage
• Lipoprotein(a) and cardiovascular disease.1 passage
• Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.1 passage
• Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.1 passage
• Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.1 passage
• Livebirth rate after one frozen embryo transfer in ovulatory women starting with natural, modified natural, or artificial endometrial preparation in Viet Nam: an open-label randomised controlled trial.1 passage
• Liver cirrhosis.1 passage
• Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.1 passage
• Loneliness in the time of COVID-19: an alarming rise.3 passages
• Long COVID and self-management.1 passage
• Long COVID guidelines need to reflect lived experience.11 passages
• Long COVID: 3 years in.8 passages
• Long COVID: a clinical update.1 passage
• Long COVID: which symptoms can be attributed to SARS-CoV-2 infection?6 passages
• Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.1 passage
• Long-haul COVID: heed the lessons from other infection-triggered illnesses.3 passages
• Long-term care for people treated for cancer during childhood and adolescence.1 passage
• Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.1 passage
• Long-term effects of COVID-19 on kidney function - Authors' reply.3 passages
• Long-term effects of COVID-19 on kidney function.2 passages
• Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial.1 passage
• Long-term effects on survivors with COVID-19 - Authors' reply.1 passage
• Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.1 passage
• Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.1 passage
• Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Long-term follow-up of recovered patients with COVID-19.6 passages
• Long-term health effects after conflict-related traumatic amputation among patients in Gaza.1 passage
• Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.1 passage
• Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial.1 passage
• Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial.1 passage
• Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine.6 passages
• Low back pain.1 passage
• Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial.1 passage
• Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.1 passage
• Lung cancer screening.1 passage
• Lung cancer.1 passage
• Lung-function trajectories: relevance and implementation in clinical practice.1 passage
• MAb for symptomatic COVID-19 in correctional facilities: an important opportunity.3 passages
• Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts.1 passage
• Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets.1 passage
• Malaria in 2022: a year of opportunity.6 passages
• Malaria.1 passage
• Male infertility.1 passage
• Malnutrition in older adults.1 passage
• Malnutrition risk in hospitalised COVID-19 patients receiving CPAP.3 passages
• Management of common clinical problems experienced by survivors of cancer.1 passage
• Management of cut wounds and lacerations in the Gaza Strip: a prospective clinical audit.1 passage
• Management of disease-related malnutrition for patients being treated in hospital.1 passage
• Managing early-onset type 2 diabetes in the individual and at the population level.1 passage
• Managing menopause after cancer.1 passage
• Mandatory COVID-19 vaccination and human rights.9 passages
• Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum and Plasmodium vivax malaria, 2000-22: a spatial and temporal modelling study.49 passages
• Marketing of commercial milk formula: a system to capture parents, communities, science, and policy.1 passage
• Martin Landray: harnessing the power of good clinical trials.5 passages
• Mass infection is not an option: we must do more to protect our young.1 passage
• Matching actions to needs: shifting policy responses to the changing health needs of Chinese children and adolescents.1 passage
• Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study.43 passages
• Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Measles.1 passage
• Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970-2019: a systematic analysis for the Global Burden of Disease Study 2019.76 passages
• Measuring progress in pregnancy planning and preconception health.1 passage
• Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1.64 passages
• Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.74 passages
• Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium.1 passage
• Media restrictions have "cost lives".10 passages
• Medical consequences of "contingency accommodation" for people seeking asylum: thematic analysis of a survey from professionals working in contingency accommodation.1 passage
• Medical cyber crises and biotechnological syndromes: a multisite clinical simulation study focused on digital health complaints.1 passage
• Medical education reforms in China.5 passages
• Medical oxygen crisis: a belated COVID-19 response.9 passages
• Medical professionalism and physician wellbeing.5 passages
• Medical, surgical, and physical treatments for Parkinson's disease.1 passage
• Medicine and the unconscious.10 passages
• Medicine, magic, and online performance.9 passages
• Meeting the health challenges of displaced populations from Ukraine.1 passage
• Memorialising COVID-19.10 passages
• Mental health after China's prolonged lockdowns.5 passages
• Mental health of the nursing and midwifery workforce in Wales during the COVID-19 pandemic: a cross-sectional analysis.1 passage
• Mental illness and suicide among physicians.42 passages
• Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.1 passage
• Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.1 passage
• Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study.1 passage
• Methotrexate to treat hand osteoarthritis with synovitis (METHODS): an Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial.1 passage
• Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.1 passage
• Midterm elections in the USA: a pivotal moment for health.6 passages
• Migraine: disease characterisation, biomarkers, and precision medicine.1 passage
• Migraine: epidemiology and systems of care.1 passage
• Migraine: integrated approaches to clinical management and emerging treatments.1 passage
• Migration and health in Latin America during the COVID-19 pandemic and beyond.6 passages
• Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.1 passage
• Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.1 passage
• Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss.1 passage
• Misclassification bias in estimating clinical severity of SARS-CoV-2 variants - Authors' reply.4 passages
• Misclassification bias in estimating clinical severity of SARS-CoV-2 variants.2 passages
• Missing again: US racial and ethnic data for COVID-19 vaccination.3 passages
• Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.1 passage
• Mitigation of respiratory syncytial virus epidemics by RSVpreF vaccines after the COVID-19 pandemic in the UK: a modelling study.1 passage
• Mixed response to COVID-19 intellectual property waiver.11 passages
• Mobilising evidence, data, and resources to achieve global maternal and child undernutrition targets and the Sustainable Development Goals: an agenda for action.1 passage
• Moderating effect of country-level health determinants on the association between hobby engagement and mental health: cross-cohort multi-level models, meta-analyses, and meta-regressions.1 passage
• Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.1 passage
• Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.54 passages
• Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.1 passage
• Monitoring inequalities is a key part of the efforts to end AIDS, tuberculosis, and malaria.1 passage
• Monkeypox PHEIC decision hoped to spur the world to act.5 passages
• Monkeypox and pregnancy: time for global surveillance and prevention strategies.2 passages
• Monkeypox as a PHEIC: implications for global health governance.9 passages
• Monkeypox exposure during pregnancy: what does UK public health guidance advise?3 passages
• Monkeypox exposure during pregnancy: what does UK public health guidance advise? - Authors' reply.4 passages
• Monkeypox genomic surveillance will challenge lessons learned from SARS-CoV-2.3 passages
• Monkeypox in the UK: arguments for a broader case definition.5 passages
• Monkeypox.69 passages
• Monkeypox: a global wake-up call.6 passages
• Monofilament suture versus braided suture thread to improve pregnancy outcomes after vaginal cervical cerclage (C-STICH): a pragmatic randomised, controlled, phase 3, superiority trial.1 passage
• Morbidity patterns among hospitalised Palestine refugees from Syria in Jordan: a population-based study.1 passage
• More equitable preconception health: paternal life course opportunities for better pregnancy, child, and family outcomes.1 passage
• More play and fewer screens: a way to improve preschoolers' mental health? Cross-sectional findings from the British Preschool-children's Play Survey.1 passage
• More than honour, humanitarian health-care workers need life-saving protection.5 passages
• Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study.58 passages
• Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.1 passage
• Mortality in randomised controlled trials using paclitaxel-coated devices for femoropopliteal interventional procedures: an updated patient-level meta-analysis.1 passage
• Moving past the COVID-19 emergency in the USA.5 passages
• Moving the dial on diagnostics: an update from the Lancet Commission on diagnostics.1 passage
• Moving towards a precision approach for prevention of severe COVID-19 - Authors' reply.2 passages
• Moving towards a precision approach for prevention of severe COVID-19.2 passages
• Mpox in people with advanced HIV infection: a global case series.1 passage
• Mpox neglect and the smallpox niche: a problem for Africa, a problem for the world.1 passage
• Multidrug-resistant Gram-negative bacterial infections.1 passage
• Multiple myeloma.1 passage
• Multiple sclerosis.1 passage
• NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.25 passages
• NCD Countdown 2030: efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income countries.67 passages
• Narrative complexity in the time of COVID-19.8 passages
• National, regional, and global estimates of low birthweight in 2020, with trends from 2000: a systematic analysis.1 passage
• National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis.1 passage
• National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050.52 passages
• Navigating from SARS-CoV-2 elimination to endemicity in Australia, Hong Kong, New Zealand, and Singapore.8 passages
• Negative pressure wound therapy versus usual care in patients with surgical wound healing by secondary intention in the UK (SWHSI-2): an open-label, multicentre, parallel-group, randomised controlled trial.49 passages
• Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.1 passage
• Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Neonatal bacterial sepsis.1 passage
• Neonatal outcomes for women at risk of preterm delivery given half dose versus full dose of antenatal betamethasone: a randomised, multicentre, double-blind, placebo-controlled, non-inferiority trial.1 passage
• Neuromodulation for chronic pain.1 passage
• Neuropathology associated with SARS-CoV-2 infection - Authors' reply.3 passages
• Neuropathology associated with SARS-CoV-2 infection.7 passages
• Neuroprotective mechanisms of exercise and the importance of fitness for healthy brain ageing.1 passage
• Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients.1 passage
• Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.1 passage
• New EU health programme comes into force.11 passages
• New Libyan Government faces health challenges.6 passages
• New WTO leader faces COVID-19 challenges.5 passages
• New beginnings for Latin America?7 passages
• New budget and strategy for ACT-A.5 passages
• New centre for pandemic therapeutics.5 passages
• New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK.46 passages
• New drug therapies for hypertension.1 passage
• New landscape of the diagnosis of Alzheimer's disease.1 passage
• New promises and challenges in the treatment of advanced non-small-cell lung cancer.1 passage
• Next-generation COVID-19 vaccines: here come the proteins.5 passages
• Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.1 passage
• Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.1 passage
• Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.1 passage
• No climate change justice in lieu of global authorship equity - Authors' reply.1 passage
• No climate change justice in lieu of global authorship equity.1 passage
• No point in travel bans if countries with poor surveillance are ignored.2 passages
• No time for complacency on COVID-19 in Europe.2 passages
• Nociplastic pain: towards an understanding of prevalent pain conditions.1 passage
• Nominees to lead PAHO announced.13 passages
• Non-alcoholic fatty liver disease.1 passage
• Non-coeliac gluten sensitivity.1 passage
• Non-communicable diseases among Palestinian refugees from Syria: a cross-sectional study on prevalence, case management, access to and utilisation of UNRWA Health Services.1 passage
• Non-communicable diseases: what now?5 passages
• Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.41 passages
• Non-surgical casting versus surgical reduction for children with severely displaced distal radial fractures (the CRAFFT Study): a multicentre, randomised, controlled non-inferiority trial and economic evaluation.1 passage
• Normobaric hyperoxia combined with endovascular treatment for acute ischaemic stroke in China (OPENS-2 trial): a multicentre, randomised, single-blind, sham-controlled trial.1 passage
• Novel and emerging treatments for major depression.1 passage
• Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation.27 passages
• Nowcasting towards sustainable SARS-CoV-2 endemicity.8 passages
• Nowcasting waiting lists for elective procedures and surgery in England: a modelling study.1 passage
• Nutrition in adolescent growth and development.1 passage
• Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial.1 passage
• Obesity in adults.1 passage
• Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation.1 passage
• Obligations in a global health emergency - Authors' reply.1 passage
• Odds of gambling among adolescents: a secondary analysis of the cross-sectional European School Survey Project on Alcohol and Other Drugs.1 passage
• Oesophageal cancer.1 passage
• Offline: ACT-A-ça suffit.6 passages
• Offline: COVID-19 and the convergence of nations.5 passages
• Offline: COVID-19 as culture war.3 passages
• Offline: Complacency threatens progress against COVID-19.5 passages
• Offline: How others see us.5 passages
• Offline: How to fix pandemic preparedness.5 passages
• Offline: It's time to ask questions and learn lessons.5 passages
• Offline: Sex and power during a pandemic.4 passages
• Offline: The UK COVID-19 Inquiry-be patient, but don't wait.5 passages
• Offline: The case for No-COVID.5 passages
• Offline: The cosmopolitan state.4 passages
• Offline: The danger of unreliable narrators.5 passages
• Offline: The generation of ghosts.4 passages
• Offline: The incontestable moral value of health.5 passages
• Offline: The lessons of smallpox eradication for COVID-19.5 passages
• Offline: The origin story-towards a final resolution?5 passages
• Offline: The origins story-towards a Deep Ecology.4 passages
• Offline: There is no right to lie.5 passages
• Offline: USA versus China-the growing insanity of our times.5 passages
• Offline: Ukraine and the lessons of Alexander Herzen.5 passages
• Offline: What is the UK for?5 passages
• Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients.10 passages
• Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.2 passages
• Omicron severity: milder but not mild.1 passage
• Omicron: fewer adverse outcomes come with new dangers.6 passages
• Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).1 passage
• Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.1 passage
• Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.1 passage
• Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.1 passage
• Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.1 passage
• Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial.1 passage
• Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial.1 passage
• Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.1 passage
• Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.1 passage
• Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.1 passage
• Oncolytic viruses as anticancer agents: clinical progress and remaining challenges.1 passage
• One Health action for health security and equity.8 passages
• Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial.1 passage
• Opioid versus opioid-free analgesia after surgical discharge: a systematic review and meta-analysis of randomised trials.1 passage
• Opportunities for chronic pain self-management: core psychological principles and neurobiological underpinnings.1 passage
• Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.1 passage
• Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial.1 passage
• Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial.1 passage
• Optimising SARS-CoV-2 vaccination schedules.4 passages
• Optimising epilepsy care throughout the Afghan refugee crisis.3 passages
• Optimising health after early menopause.1 passage
• Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial.1 passage
• Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.1 passage
• Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials.1 passage
• Oral health problems are global and need to be addressed in the USA.1 passage
• Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study.1 passage
• Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.1 passage
• Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.1 passage
• Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.1 passage
• Osteoarthritis.1 passage
• Osteoporosis.1 passage
• Our commitment to help accelerate progress against cancer.5 passages
• Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.1 passage
• Outcomes after surgery for children in Africa (ASOS-Paeds): a 14-day prospective observational cohort study.1 passage
• Outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves: a registry study.1 passage
• Outsourcing and children's social care services: an observational longitudinal analysis of inspection outcomes among English children's homes and local authorities.1 passage
• Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.49 passages
• Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.1 passage
• Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.1 passage
• Oxford-AstraZeneca COVID-19 vaccine efficacy.8 passages
• PANORAMIC: important insights into molnupiravir use in COVID-19.6 passages
• PREZODE: preventing zoonotic disease emergence.4 passages
• Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial.1 passage
• Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial.1 passage
• Pain management in adults during long-bone fracture reduction in the Gaza Strip: a clinical audit.1 passage
• Pancreatic cancer.1 passage
• Pandemic moves and countermoves: vaccines and viral variants.5 passages
• Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021.54 passages
• Pandemic preparedness means policy makers need to work with social scientists.1 passage
• Pandemic solidarity across national borders saved lives.2 passages
• Parent-focused behavioural interventions for the prevention of early childhood obesity (TOPCHILD): a systematic review and individual participant data meta-analysis.1 passage
• Parental and health visitor perceptions on growth screening in early childhood: a qualitative study.1 passage
• Parental education and inequalities in child mortality: a global systematic review and meta-analysis.50 passages
• Parenting in the time of COVID-19.4 passages
• Parkinson's disease.1 passage
• Partial progress in sexual and reproductive health and rights: the influence of sociocultural, behavioural, structural, and technological changes on epidemiological trends.1 passage
• Participation of people living with disabilities in physical activity: a global perspective.1 passage
• Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study.1 passage
• Passive anti-amyloid β immunotherapy in Alzheimer's disease-opportunities and challenges.1 passage
• Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis.45 passages
• Past and present women pioneers in biomedical science.16 passages
• Pathophysiology from preconception, during pregnancy, and beyond.1 passage
• Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study.46 passages
• Patient journey and costs through a brain health clinic compared with a memory clinic: a costing study.1 passage
• Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.1 passage
• Pay gaps in medicine and the impact of COVID-19 on doctors' careers.7 passages
• Peer effects on health-related behaviours of adolescents in Scotland using social network analysis: a cross-sectional study.1 passage
• Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.1 passage
• Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.1 passage
• Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.1 passage
• Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.1 passage
• Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.1 passage
• Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.1 passage
• Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.1 passage
• Peptic ulcer disease.1 passage
• Perceptions of health-care professionals about quality of care and barriers to management of war injuries in Gaza Strip: a qualitative analysis.1 passage
• Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial.1 passage
• Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis.1 passage
• Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial.1 passage
• Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study.1 passage
• Perilous two-tier COVID-19 global vaccine roll-out.2 passages
• Perinatal morbidity among women with a previous caesarean delivery (PRISMA trial): a cluster-randomised trial.1 passage
• Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.1 passage
• Peripartum cardiomyopathy.1 passage
• Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study.41 passages
• Persistent physical symptoms: definition, genesis, and management.1 passage
• Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial.1 passage
• Perspectives on registration to primary care from inclusion health groups in England: a mixed-method study.1 passage
• Peruvian COVID-19 vaccine scandal spreads.5 passages
• Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study.1 passage
• Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.37 passages
• Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.1 passage
• Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.2 passages
• Physical activity behaviours in adolescence: current evidence and opportunities for intervention.1 passage
• Physical activity in outdoor spaces, sleep quality and general health: a pilot feasibility study.1 passage
• Physical health of care-experienced young children in high-income countries: a scoping review.1 passage
• Physical punishment and child outcomes: a narrative review of prospective studies.1 passage
• Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial.1 passage
• Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.1 passage
• Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial.51 passages
• Plugging the medical brain drain.7 passages
• Policies to halt and reverse the rise in ultra-processed food production, marketing, and consumption.1 passage
• Policy innovations to advance equity in solid organ transplantation.1 passage
• Polish Government COVID-19 advisors resign.7 passages
• Political science and global health policy.6 passages
• Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process.1 passage
• Polymyalgia rheumatica.1 passage
• Population health outcomes in Nigeria compared with other west African countries, 1998-2019: a systematic analysis for the Global Burden of Disease Study.37 passages
• Population immunity and vaccine protection against infection.6 passages
• Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000-20: a retrospective analysis.1 passage
• Population-level contribution of interpersonal discrimination to psychological distress among Australian Aboriginal and Torres Strait Islander adults, and to Indigenous-non-Indigenous inequities: cross-sectional analysis of a community-controlled First Nations cohort study.1 passage
• Population-level interventions for the primary prevention of dementia: a complex evidence review.1 passage
• Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020.95 passages
• Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.1 passage
• Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial.1 passage
• Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).1 passage
• Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial.1 passage
• Postgraduate training abroad and migration intentions of medical doctors and students in Gaza: a cross-sectional survey.1 passage
• Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study.1 passage
• Potential impact of health communications to raise awareness of the relative risk of age and cancer: a qualitative study.1 passage
• Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.1 passage
• Pre-eclampsia.1 passage
• Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study.1 passage
• Pregnancy and the liver.1 passage
• Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis.56 passages
• Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study.59 passages
• Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.1 passage
• Preparing for a COVID-19 resurgence in the WHO African region.3 passages
• Preparing for future pandemics in the Eastern Mediterranean region.1 passage
• Preparing for uncertainty: endemic paediatric viral illnesses after COVID-19 pandemic disruption.9 passages
• Prevalence and characteristics of Palestine refugee mothers at risk of postpartum depression in Amman, Jordan: a cross-sectional study.1 passage
• Prevalence and nature of workplace bullying and harassment and associations with mental health conditions in England: a cross-sectional probability sample survey.1 passage
• Prevalence of adolescent mental disorders in Kenya, Indonesia, and Viet Nam measured by the National Adolescent Mental Health Surveys (NAMHS): a multi-national cross-sectional study.1 passage
• Prevalence of chronic diseases in older Palestinian adults and common pharmacological interventions: a cross-sectional study.1 passage
• Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.1 passage
• Prevalence of negative child disciplinary practices and its associated factors as reported by mothers in the West Bank: a cross-sectional study.1 passage
• Prevalence of overweight, obesity, and associated factors among adolescents in the occupied Palestinian territory: a cross-sectional study.1 passage
• Prevalence of sexual violence against children and age at first exposure: a global analysis by location, age, and sex (1990-2023).75 passages
• Prevention of heart failure after acute myocardial infarction.1 passage
• Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention.1 passage
• Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.1 passage
• Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.48 passages
• Primary biliary cholangitis.1 passage
• Primary brain tumours in adults.1 passage
• Primary health care: a cornerstone of pandemic prevention, preparedness, response, and recovery.3 passages
• Primary sclerosing cholangitis.1 passage
• Priorities for COVID-19 research response and preparedness in low-resource settings.8 passages
• Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission.8 passages
• Prioritisation of COVID-19 boosters in the omicron era.7 passages
• Prioritising immunisation across the life course.1 passage
• Prioritising the primary prevention of heart failure.1 passage
• Profiles of tobacco smokers and ex-smokers in a large-scale random sample survey across Wales: an unsupervised machine-learning cluster analysis.1 passage
• Profiling vaccine attitudes and subsequent uptake in 1·1 million people in England: a nationwide cohort study.1 passage
• Prognostic accuracy of clinical markers of postpartum bleeding in predicting maternal mortality or severe morbidity: a WHO individual participant data meta-analysis.52 passages
• Progress in health among regions of Ethiopia, 1990-2019: a subnational country analysis for the Global Burden of Disease Study 2019.49 passages
• Progress towards the WHO Global Initiative for Childhood Cancer target of 60% 5-year survival for all childhood cancers combined, 1990-2019 (CONCORD-4): a Cancer Survival Index derived for 68 countries by analysis of individual records for 613 021 children from 307 population-based cancer registries.1 passage
• Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial.58 passages
• Projecting COVID-19 disruption to elective surgery.1 passage
• Prolonged grief disorder.1 passage
• Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.35 passages
• Promoting good mental health over the menopause transition.1 passage
• Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Prostate cancer.2 passages
• Protecting Africa's children from extreme risk: a runway of sustainability for PEPFAR programmes.1 passage
• Protecting older people: a high priority during the COVID-19 pandemic.5 passages
• Protecting refugees during the COVID-19 pandemic.5 passages
• Protecting the health of children with universal child cash benefits.1 passage
• Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.49 passages
• Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial.1 passage
• Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial.1 passage
• Psoriasis.1 passage
• Public health qualifications, motivation, and experience of pharmacy professionals: exploratory cross-sectional surveys of pharmacy and public health professionals.1 passage
• Pyruvate kinase activators in hereditary haemolytic anaemias: current evidence and clinical potential.1 passage
• Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.1 passage
• Quality assurance of remote clinical assessments in the NHS.3 passages
• Quality of Early Essential Newborn Care in hospitals in Gaza: a pre-intervention and post-intervention study.1 passage
• Quantifying relative health impact across Gavi, the Vaccine Alliance's portfolio in 117 countries at the subregional level: a modelling study.1 passage
• Quantifying the effects of the COVID-19 pandemic on gender equality on health, social, and economic indicators: a comprehensive review of data from March, 2020, to September, 2021.60 passages
• Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial.1 passage
• Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• RETRACTED: Chinese medical personnel after the COVID-19 pandemic.3 passages
• Racial disparities in recommendations for surgical resection of primary brain tumours: a registry-based cohort analysis.1 passage
• Racial inequities in homicide rates and homicide methods among Black and White women aged 25-44 years in the USA, 1999-2020: a cross-sectional time series study.1 passage
• Racism in the USA: ensuring Asian American health equity.5 passages
• Racism, xenophobia, and discrimination: mapping pathways to health outcomes.1 passage
• Racism, xenophobia, discrimination, and the determination of health.1 passage
• Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.1 passage
• Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials.1 passage
• Radiotherapy toxicities: mechanisms, management, and future directions.1 passage
• Raj Panjabi: bringing a global outlook to the US pandemic response.6 passages
• Ramadan and COVID-19 vaccine hesitancy-a call for action.1 passage
• Rapid identification and tracking of SARS-CoV-2 variants of concern.3 passages
• Rates and causes of death after release from incarceration among 1 471 526 people in eight high-income and middle-income countries: an individual participant data meta-analysis.1 passage
• Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs.3 passages
• Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).47 passages
• Reaffirming health and safety precautionary principles for COVID-19 in the UK.2 passages
• Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.35 passages
• Real-world effectiveness of oral antivirals for COVID-19.1 passage
• Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.1 passage
• Reconsidering the COVID-19 vaccine strategy in West and Central Africa.3 passages
• Recording and analysing ethnicity in public health research: a bibliographical review and focus group discussions with young migrants and refugees in the UK.1 passage
• Recovering from Trump: Biden's first 100 days.24 passages
• Recurrent miscarriage: evidence to accelerate action.1 passage
• Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis.39 passages
• Reduced mortality in New Zealand during the COVID-19 pandemic.3 passages
• Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.7 passages
• Reducing surgical site infections in low-income and middle-income countries (FALCON): a pragmatic, multicentre, stratified, randomised controlled trial.55 passages
• Reducing the drivers of drug demand in English towns by understanding risk and resilience in the community and developing a framework for partnership action: a mixed methods analysis.1 passage
• Reducing the health effects of hot weather and heat extremes: from personal cooling strategies to green cities.1 passage
• Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.1 passage
• Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial.1 passage
• Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.42 passages
• Reflecting on parental insights into healthy lifestyles: a qualitative study.1 passage
• Rehabilitation versus surgical reconstruction for non-acute anterior cruciate ligament injury (ACL SNNAP): a pragmatic randomised controlled trial.1 passage
• Reimagining India's health system: a Lancet Citizens' Commission.7 passages
• Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.1 passage
• Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients.1 passage
• Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.60 passages
• Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial.1 passage
• Renal cell carcinoma.1 passage
• Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial.1 passage
• Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Report of the Independent Panel for Pandemic Preparedness and Response: making COVID-19 the last pandemic.16 passages
• Report of the Lancet Commission on the Value of Death: bringing death back into life.295 passages
• Research Focus: Protas.11 passages
• Research collaboration is needed to inform quarantine policies for health-care workers.3 passages
• Research in forced displacement: guidance for a feminist and decolonial approach.10 passages
• Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.1 passage
• Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study.1 passage
• Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children.1 passage
• Responding to health emergencies in the Eastern Mediterranean region in times of conflict.7 passages
• Responding to the Türkiye-Syria earthquake: what will it take?5 passages
• Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence.9 passages
• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.1 passage
• Rethinking how development assistance for health can catalyse progress on primary health care.1 passage
• Rethinking vaccine hesitancy among minority groups.8 passages
• Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.1 passage
• Retraction-Chinese medical personnel after the COVID-19 pandemic.1 passage
• Retroperitoneal fibrosis.1 passage
• Revisiting maternal and child undernutrition in low-income and middle-income countries: variable progress towards an unfinished agenda.42 passages
• Revisiting the evidence for physical distancing, face masks, and eye protection.1 passage
• Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.1 passage
• Rheumatoid arthritis.1 passage
• Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.1 passage
• Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.1 passage
• Risk markers for sudden unexpected death in epilepsy: an observational, prospective, multicentre cohort study.1 passage
• Risk of SARS-CoV-2 reinfection after natural infection.5 passages
• Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study.38 passages
• Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.38 passages
• Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2.6 passages
• Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.35 passages
• Ritonavir and COVID-19: pragmatic guidance is important.3 passages
• Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.54 passages
• Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.49 passages
• Role of preoperative in-hospital delay on appendiceal perforation while awaiting appendicectomy (PERFECT): a Nordic, pragmatic, open-label, multicentre, non-inferiority, randomised controlled trial.1 passage
• Ros Taylor: seeing palliative care as relational.5 passages
• Routine immunisations: reversing the decline.6 passages
• Routine sterile glove and instrument change at the time of abdominal wound closure to prevent surgical site infection (ChEETAh): a pragmatic, cluster-randomised trial in seven low-income and middle-income countries.1 passage
• Rubella.1 passage
• SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial.1 passage
• SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.1 passage
• SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses.5 passages
• SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination.1 passage
• SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties.7 passages
• SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN).47 passages
• SARS-CoV-2 nucleic acid testing is China's key pillar of COVID-19 containment.1 passage
• SARS-CoV-2 serosurveys in low-income and middle-income countries.6 passages
• SARS-CoV-2 vaccination in pregnancy: a unique opportunity for equity.1 passage
• SARS-CoV-2 variants and ending the COVID-19 pandemic.9 passages
• SARS-CoV-2's origin should be investigated worldwide for pandemic prevention.1 passage
• SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.1 passage
• SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.1 passage
• SOS Brazil: democracy under attack.4 passages
• SOS Brazil: science under attack.4 passages
• Safeguarding and teleconsultation for abortion.18 passages
• Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study.1 passage
• Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.1 passage
• Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.56 passages
• Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial.1 passage
• Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.1 passage
• Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke (OPTIMISTmain): an international, pragmatic, stepped-wedge, cluster-randomised, controlled non-inferiority trial.1 passage
• Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.40 passages
• Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study.1 passage
• Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.1 passage
• Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.1 passage
• Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials.1 passage
• Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.1 passage
• Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.1 passage
• Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.72 passages
• Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.1 passage
• Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.58 passages
• Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.52 passages
• Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study.1 passage
• Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.1 passage
• Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.49 passages
• Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.46 passages
• Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.48 passages
• Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.79 passages
• Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.51 passages
• Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.56 passages
• Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.49 passages
• Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.1 passage
• Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.55 passages
• Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.1 passage
• Safety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial.1 passage
• Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.1 passage
• Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.1 passage
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.1 passage
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.1 passage
• Saving lives through road safety risk factor interventions: global and national estimates.1 passage
• Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.1 passage
• Scale up task-sharing of psychological therapies.1 passage
• Scheduled birth at term for the prevention of pre-eclampsia (PREVENT-PE): an open-label randomised controlled trial.1 passage
• Schizophrenia.1 passage
• School reopening without robust COVID-19 mitigation risks accelerating the pandemic.9 passages
• Science during COVID-19: where do we go from here?5 passages
• Science, not speculation, is essential to determine how SARS-CoV-2 reached humans.8 passages
• Scientific advances in the assessment, modification, and generation of transplantable organs for patients with end-stage organ diseases.1 passage
• Scientific misinformation.2 passages
• Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy.40 passages
• Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.1 passage
• Securing a sustainable and fit-for-purpose UK health and care workforce.92 passages
• Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.1 passage
• Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial.1 passage
• Self-guided digital behavioural therapy versus active control for fibromyalgia (PROSPER-FM): a phase 3, multicentre, randomised controlled trial.1 passage
• Self-perceived health among children with spina bifida in the West Bank: a cross-sectional study.1 passage
• Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.1 passage
• Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.1 passage
• Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.1 passage
• Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.1 passage
• Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.1 passage
• Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.1 passage
• Sepsis.1 passage
• Serbia begins paying citizens to receive a COVID-19 vaccine.5 passages
• Serial intervals in SARS-CoV-2 B.1.617.2 variant cases.6 passages
• Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.47 passages
• Setbacks in the quest for universal health coverage in Mexico: polarised politics, policy upheaval, and pandemic disruption.1 passage
• Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.53 passages
• Severe mental illness: reassessing COVID-19 vaccine priorities.5 passages
• Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies.1 passage
• Sex-disaggregated data in COVID-19 vaccine trials.3 passages
• Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational analysis with external cohort validation.1 passage
• Sexual behaviours and clinical course of human monkeypox in Spain.7 passages
• Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic.6 passages
• Shelter is key to delivering on COP27 commitments.5 passages
• Shifting gender barriers in immunisation in the COVID-19 pandemic response and beyond.3 passages
• Shifting priorities and employment choices among workers in Wales during the COVID-19 pandemic: a longitudinal analysis.1 passage
• Shigellosis.1 passage
• Short, medium, and long deferral of umbilical cord clamping compared with umbilical cord milking and immediate clamping at preterm birth: a systematic review and network meta-analysis with individual participant data.1 passage
• Sickle cell disease.1 passage
• Singapore's health-care system: key features, challenges, and shifts.1 passage
• Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster.5 passages
• Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.55 passages
• Sisonke: reaching several goals together.1 passage
• Skin lesion specimens as first choice to detect monkeypox virus - Authors' reply.1 passage
• Skin lesion specimens as first choice to detect monkeypox virus.2 passages
• Small babies, big risks: global estimates of prevalence and mortality for vulnerable newborns to accelerate change and improve counting.1 passage
• Small vulnerable newborns-big potential for impact.1 passage
• So far, no novel SARS-CoV-2 variants from Beijing-and hopefully better scientific cooperation going forward.6 passages
• Social determinants of mental health trajectories during midlife: a prospective British birth cohort study.1 passage
• Social return on investment of face-to-face versus online lifestyle coaching to improve mental wellbeing.1 passage
• Social unrest disrupts South African health care.4 passages
• Societal implications of the Dobbs v Jackson Women's Health Organization decision.1 passage
• Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study.1 passage
• Socioeconomic inequalities in cancer survival and access to health care among children and adolescents in China, 2018-24: a prospective nationwide cohort study.1 passage
• Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.1 passage
• Solar-powered O2 delivery for the treatment of children with hypoxaemia in Uganda: a stepped-wedge, cluster randomised controlled trial.1 passage
• Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.1 passage
• South Africa responds to new SARS-CoV-2 variant.5 passages
• Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.1 passage
• Spatial agency among children living in the Dheisheh refugee camp in the West Bank: a qualitative investigation of space and place as risk and protection factors from political and military violence.1 passage
• Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019.62 passages
• Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort.1 passage
• Speed up multi-pathogen surveillance.2 passages
• Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.1 passage
• Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.1 passage
• Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.1 passage
• Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.1 passage
• Spontaneous subarachnoid haemorrhage.1 passage
• Sporadic miscarriage: evidence to provide effective care.1 passage
• Sputnik V COVID-19 vaccine candidate appears safe and effective.4 passages
• Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.1 passage
• Statelessness in the COVID-19 pandemic.10 passages
• Steatotic liver disease.1 passage
• Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.1 passage
• Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial.1 passage
• Stigma and discrimination and its homeless and health system contexts in south London: an ethnographic case study.1 passage
• Stigma, vaccination, and moral accountability.1 passage
• Stopping epidemics when and where they occur.21 passages
• Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.1 passage
• Strategic imperatives for health in the USA: a roadmap for the incoming presidential administration.1 passage
• Strategies and interventions for healthy adolescent growth, nutrition, and development.1 passage
• Strengthening public mental health during and after the acute phase of the COVID-19 pandemic.7 passages
• Strengthening the reporting of stillbirths globally - Authors' reply.3 passages
• Strengthening the reporting of stillbirths globally.3 passages
• Striving for balance in decisions on antenatal pharmacotherapy.1 passage
• Stroke.1 passage
• Structural medicine: towards an economy of care.7 passages
• Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.52 passages
• Studying the coagulopathy of COVID-19.6 passages
• Subacromial balloon spacer for irreparable rotator cuff tears of the shoulder (START:REACTS): a group-sequential, double-blind, multicentre randomised controlled trial.1 passage
• Substantial increases in cervical cancer inequalities worldwide without enhanced human papillomavirus vaccination and screening efforts: a global modelling study.1 passage
• Suicide and self-harm.1 passage
• Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial.1 passage
• Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.1 passage
• Surge of lower respiratory tract group A streptococcal infections in England in winter 2022: epidemiology and clinical profile.1 passage
• Surgery versus corticosteroid injection for carpal tunnel syndrome (DISTRICTS): an open-label, multicentre, randomised controlled trial.1 passage
• Surgical fixation versus non-surgical care for children with a displaced medial epicondyle fracture of the elbow (the SCIENCE study): a multicentre, randomised controlled, superiority trial and economic evaluation.1 passage
• Surgical health policy 2025-35: strengthening essential services for tomorrow's needs.1 passage
• Survival analysis for patients with cancer in Gaza applying for Israeli permits to exit the Gaza Strip for health care: a retrospective cohort study of patients from 2008 to 2017.1 passage
• Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials.1 passage
• Surviving stomach bugs in UK ethnic groups: a qualitative study.1 passage
• Survivorship of modern total hip replacement to 30 years: systematic review, meta-analysis, and extrapolation of global joint registry data.1 passage
• Suspected and confirmed mpox cases in DR Congo: a retrospective analysis of national epidemiological and laboratory surveillance data, 2010-23.1 passage
• Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance.1 passage
• Sustained neutralising antibodies in the Wuhan population suggest durable protection against SARS-CoV-2.5 passages
• Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial.1 passage
• Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.1 passage
• Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.1 passage
• Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.1 passage
• Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.32 passages
• Syphilis.1 passage
• Systemic lupus erythematosus.1 passage
• Systemic sclerosis.1 passage
• T-cell-engaging bispecific antibodies in cancer.1 passage
• TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198.1 passage
• Tackling Latin America's COVID-19 emergency requires greater solidarity.2 passages
• Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.1 passage
• Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.1 passage
• Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.1 passage
• Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.1 passage
• Tanzania refuses COVID-19 vaccines.4 passages
• Tanzania's COVID-19 vaccination strategy: lessons, learning, and execution.4 passages
• Targeted prophylactic anticoagulation based on the TRiP(cast) score in patients with lower limb immobilisation: a multicentre, stepped wedge, randomised implementation trial.1 passage
• Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunities.1 passage
• Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.1 passage
• Telerehabilitation consultations with a physiotherapist for chronic knee pain versus in-person consultations in Australia: the PEAK non-inferiority randomised controlled trial.1 passage
• Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up.1 passage
• Ten Americas: a systematic analysis of life expectancy disparities in the USA.52 passages
• Ten scientific reasons in support of airborne transmission of SARS-CoV-2.10 passages
• Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.1 passage
• Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial.1 passage
• Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.1 passage
• Term planned delivery based on fetal growth assessment with or without the cerebroplacental ratio in low-risk pregnancies (RATIO37): an international, multicentre, open-label, randomised controlled trial.1 passage
• Testicular cancer.1 passage
• Tetanus.1 passage
• Thalassaemia.1 passage
• The 2020 report of The Lancet Countdown on health and climate change: responding to converging crises.187 passages
• The 2021 report of the Lancet Countdown on health and climate change: code red for a healthy future.203 passages
• The 2022 report of the Lancet Countdown on health and climate change: health at the mercy of fossil fuels.138 passages
• The 2023 report of the Lancet Countdown on health and climate change: the imperative for a health-centred response in a world facing irreversible harms.215 passages
• The 2024 report of the Lancet Countdown on health and climate change: facing record-breaking threats from delayed action.224 passages
• The ACT Accelerator: heading in the right direction?6 passages
• The African Critical Illness Outcomes Study (ACIOS): a point prevalence study of critical illness in 22 nations in Africa.45 passages
• The CEPI centralised laboratory network: supporting COVID-19 vaccine development.3 passages
• The COVID-19 vaccines rush: participatory community engagement matters more than ever.8 passages
• The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines.8 passages
• The Global Fund: replenishment and future-proofing.6 passages
• The Health and Care Act 2022: challenges and priorities for embedding research in the NHS.1 passage
• The Lancet 1823-2023: the best science for better lives.1 passage
• The Lancet Commission on 21st-Century Global Health Threats.5 passages
• The Lancet Commission on diagnostics: transforming access to diagnostics.348 passages
• The Lancet Commission on lessons for the future from the COVID-19 pandemic.292 passages
• The Lancet Commission on prostate cancer: planning for the surge in cases.147 passages
• The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma.1 passage
• The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action.1 passage
• The Lancet Countdown on health and plastics.1 passage
• The Lancet Nigeria Commission: investing in health and the future of the nation.275 passages
• The Lancet and colonialism: past, present, and future.1 passage
• The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030.1 passage
• The NHS: the many challenges for leadership.4 passages
• The Peer Education Project to improve mental health literacy in secondary school students in England: a qualitative realist evaluation.1 passage
• The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.46 passages
• The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.45 passages
• The Sussex COVID-19 Modelling Cell: the methods and successes of a collaboration between public health teams in local authorities, NHS hospital trusts, NHS commissioners, and universities.1 passage
• The São Paulo Declaration on Planetary Health.2 passages
• The Tokyo 2020 and Beijing 2022 Olympic Games held during the COVID-19 pandemic: planning, outcomes, and lessons learnt.1 passage
• The UK COVID-19 Inquiry must examine the foundations of pandemic decision making.1 passage
• The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world.11 passages
• The UK People's Covid Inquiry.3 passages
• The USA's response to the 2014 Ebola outbreak could have informed its COVID-19 response.7 passages
• The World Health Network: a global citizens' initiative.1 passage
• The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.1 passage
• The burden of diseases, injuries, and risk factors by state in the USA, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.95 passages
• The case for optimal investment in combating HIV, tuberculosis, and malaria: a global modelling study.1 passage
• The changing face of medical professionalism and the impact of COVID-19.5 passages
• The changing health needs of the UK population.55 passages
• The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.1 passage
• The clinical effect of point-of-care HIV diagnosis in infants: a systematic review and meta-analysis.1 passage
• The clinical effectiveness of clarithromycin versus endoscopic sinus surgery for adults with chronic rhinosinusitis with and without nasal polyps (MACRO): a pragmatic, multicentre, three-arm, randomised, placebo-controlled phase 4 trial.1 passage
• The complex causes of India's 2021 COVID-19 surge.2 passages
• The cost of not investing in the next 1000 days: implications for policy and practice.1 passage
• The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a cluster randomised stepped-wedge trial.1 passage
• The effect of higher protein dosing in critically ill patients with high nutritional risk (EFFORT Protein): an international, multicentre, pragmatic, registry-based randomised trial.1 passage
• The effect of home-based care on housebound patients and their caregivers in two Palestinian refugee camps in Lebanon: a qualitative study.1 passage
• The effect of indoor soundscape on sexual wellbeing during the COVID-19 lockdown in London: a thematic analysis of remote workers' experiences.1 passage
• The effect of tranexamic acid on postpartum bleeding in women with moderate and severe anaemia (WOMAN-2): an international, randomised, double-blind, placebo-controlled trial.1 passage
• The effect of two midwives during the second stage of labour to reduce severe perineal trauma (Oneplus): a multicentre, randomised controlled trial in Sweden.1 passage
• The effect of vitamin B12 supplementation during pregnancy on infant growth and development in Nepal: a community-based, double-blind, randomised, placebo-controlled trial.1 passage
• The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis.1 passage
• The effects of armed conflict on the health of women and children.1 passage
• The effects of government-led cash transfer programmes on behavioural and health determinants of mortality: a difference-in-differences study.1 passage
• The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.1 passage
• The end, and what comes after.9 passages
• The epidemiology of Parkinson's disease.1 passage
• The escalating tuberculosis crisis in central and South American prisons.1 passage
• The evolution of the Italian National Health Service.1 passage
• The evolving landscape of pulmonary arterial hypertension clinical trials.1 passage
• The experience of family carers of children with incurable cancer: a qualitative study from the occupied Palestinian territory.1 passage
• The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study.35 passages
• The forgotten girls: the state of evidence for health interventions for pregnant adolescents and their newborns in low-income and middle-income countries.1 passage
• The fragility of abortion access in Europe: a public health crisis in the making.1 passage
• The future of Iran's health workforce.3 passages
• The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches.1 passage
• The future of type 1 diabetes therapy.1 passage
• The future of valvular heart disease assessment and therapy.1 passage
• The global COVID-19 treatment divide.17 passages
• The global blood donation index: an imperfect measure of transfusion need.1 passage
• The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019.53 passages
• The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.48 passages
• The health burden of air pollution in the UK: a modelling study using updated exposure-risk associations.1 passage
• The heterogeneous effects of China's hierarchical medical system reforms on health service utilisation and health outcomes among elderly populations: a longitudinal quasi-experimental study.1 passage
• The hijacking of science and truth by political conflict.2 passages
• The impact of e-health system implementation on UNWRA health services: an observational study.1 passage
• The impact of risk stratification by polygenic risk and age on breast cancer screening in women aged 40-49 years: a modelling study.1 passage
• The impact of the COVID-19 pandemic on people experiencing homelessness: a qualitative interview study in the UK.1 passage
• The impact of urbanisation on the cardiometabolic health of Indigenous Brazilian peoples: a systematic review and meta-analysis, and data from the Brazilian Health registry.1 passage
• The importance of accountability in tackling future pandemics.2 passages
• The inverse care law re-examined: a global perspective.1 passage
• The legacy of the COVID-19 pandemic for childhood vaccination in the USA.20 passages
• The long road ahead for COVID-19 vaccination in Africa.11 passages
• The long-term impact of COVID-19 on development assistance for health is still uncertain.5 passages
• The medical right to repair: the right to save lives.1 passage
• The message on malaria is clear: progress has stalled.1 passage
• The monkeypox case definition in the UK is broad - Authors' reply.4 passages
• The monkeypox case definition in the UK is broad.2 passages
• The monkeypox outbreak is amplifying hidden voices in the global discourse.2 passages
• The motives, academic performance, and career prospects of Gazan medical students abroad: a cross-sectional study.1 passage
• The multispeciality approach to the management of localised kidney cancer.1 passage
• The need for a global COVID-19 maternal immunisation research plan.5 passages
• The need to prioritise childhood tuberculosis case detection.7 passages
• The next 1000 days: building on early investments for the health and development of young children.1 passage
• The next steps for US vaccine mandates.6 passages
• The opioid crisis and HIV in the USA: deadly synergies.1 passage
• The paradox of trust in health care in the age of social media.1 passage
• The path to global equity in mental health care in the context of COVID-19.10 passages
• The path to healthy ageing in China: a Peking University-Lancet Commission.1 passage
• The pathogenesis of Parkinson's disease.1 passage
• The persistent and evolving HIV epidemic in American men who have sex with men.1 passage
• The political and security dimensions of the humanitarian health response to violent conflict.1 passage
• The political and social contexts of global road safety: challenges for the next decade.1 passage
• The political economy of infant and young child feeding: confronting corporate power, overcoming structural barriers, and accelerating progress.1 passage
• The political theatre of the UK's travel ban on South Africa.1 passage
• The politics of universal health coverage.1 passage
• The prevalence and risk factors of urinary incontinence among women with type 2 diabetes in the north West Bank: a cross-sectional study.1 passage
• The prevalence of diabetic peripheral neuropathy among diabetic Palestinian refugees in the Nuzha area, Jordan: a cross-sectional study.1 passage
• The psychological impact of deprivation in regions affected by conflict: a multilevel analysis of a cross-sectional survey in the occupied Palestinian territory.1 passage
• The race to make a COVID-19 vaccine.10 passages
• The relationship between climate change, health, and the humanitarian response.7 passages
• The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review.37 passages
• The role of community-based blood pressure screening in improving hypertension care.1 passage
• The role of police enforcement in public health emergencies.2 passages
• The role of structural racism and geographical inequity in diabetes outcomes.1 passage
• The role of the multiple Index of deprivation in predicting mental health outcomes after the COVID-19 pandemic in adolescents: a cross-sectional study.1 passage
• The roots of social medicine: a story of relationships.8 passages
• The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.1 passage
• The scope of the antimicrobial resistance challenge.1 passage
• The shared ethical framework to allocate scarce medical resources: a lesson from COVID-19.41 passages
• The state of science and society in 2022.6 passages
• The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial.59 passages
• The ultra-processed food content of school meals and packed lunches in the UK, 2008-17: a pooled cross-sectional study.1 passage
• The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019.62 passages
• The use of inhaled corticosteroids in early-stage COVID-19.6 passages
• The vaccinated proportion of people with COVID-19 needs context.1 passage
• The value of vaccine programme impact monitoring during the COVID-19 pandemic.5 passages
• The wider health and wellbeing needs of those accessing paediatric care in England: engaging with the hidden voices of children and young people.1 passage
• Theranos and the scientific community: at the bleeding edge.6 passages
• Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.45 passages
• Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.1 passage
• Thinking across disciplinary boundaries in a time of crisis.7 passages
• Three-dose vaccination elicits neutralising antibodies against omicron.12 passages
• Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial.1 passage
• Thrombectomy for anterior circulation stroke beyond 6 h from time last known well (AURORA): a systematic review and individual patient data meta-analysis.1 passage
• Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?1 passage
• Thyroid cancer.1 passage
• Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial.1 passage
• Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.1 passage
• Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial.1 passage
• Time to reconceptualise health systems.1 passage
• Time to reimagine India's health system.2 passages
• Time to scale up mental health care in China.2 passages
• Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.1 passage
• Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.1 passage
• Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.1 passage
• Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.1 passage
• Tocilizumab in COVID-19: some clarity amid controversy.6 passages
• Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.46 passages
• Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.1 passage
• Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial.1 passage
• Towards a European strategy to address the COVID-19 pandemic.1 passage
• Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission.1 passage
• Towards unified global action on ultra-processed foods: understanding commercial determinants, countering corporate power, and mobilising a public health response.1 passage
• Trachoma.56 passages
• Tracing the temporal trends of modifiable risk factors in dementia: insights from the English Longitudinal Study of Ageing (2004-2019).1 passage
• Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990-2050.77 passages
• Tracking development assistance for health, 1990-2030: historical trends, recent cuts, and outlook.36 passages
• Traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trial.1 passage
• Trajectories of depressive symptoms 10 years after stroke and associated risk factors: a prospective cohort study.1 passage
• Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.59 passages
• Tranexamic acid for postpartum bleeding: a systematic review and individual patient data meta-analysis of randomised controlled trials.33 passages
• TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and complex or multivessel coronary disease (TCW): an international, multicentre, prospective, open-label, non-inferiority, randomised controlled trial.1 passage
• Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.1 passage
• Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study.1 passage
• Transcatheter aortic valve implantation with the Trilogy valve for symptomatic native aortic regurgitation (ALIGN-AR): a pivotal, multicentre, single-arm, investigational device exemption study.1 passage
• Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham-controlled, multicentre trial.1 passage
• Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.1 passage
• Transformative experiences and A Young Doctor's Notebook.5 passages
• Transforming access to diagnostics: how to turn good intentions into action?6 passages
• Transforming mental health systems globally: principles and policy recommendations.1 passage
• Transforming or tinkering: the world remains unprepared for the next pandemic threat.1 passage
• Transforming the UK's diagnostics agenda after COVID-19.3 passages
• Transmission of SARS-CoV-2 delta variant (AY.127) from pet hamsters to humans, leading to onward human-to-human transmission: a case study.41 passages
• Transmission of SARS-CoV-2: still up in the air - Authors' reply.1 passage
• Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.1 passage
• Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.1 passage
• Trauma care supported through a global telemedicine initiative during the 2023-24 military assault on the Gaza Strip, occupied Palestinian territory: a case series.1 passage
• Traumatic injury mortality in the Gaza Strip from Oct 7, 2023, to June 30, 2024: a capture-recapture analysis.1 passage
• Travel measures in the SARS-CoV-2 variant era need clear objectives.7 passages
• Treatment for Alzheimer's disease.1 passage
• Treatment of fibrotic interstitial lung disease: current approaches and future directions.1 passage
• Treatment of severe symptomatic aortic valve stenosis using non-invasive ultrasound therapy: a cohort study.1 passage
• Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.1 passage
• Trends in the global, regional, and national burden of oral conditions from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021.1 passage
• Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial.1 passage
• Triple jeopardy: disabled people and the COVID-19 pandemic.8 passages
• Trust made the difference for democracies in COVID-19.5 passages
• Tuberculosis.1 passage
• Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.51 passages
• Type 1 diabetes.1 passage
• Type 2 diabetes.1 passage
• Type of goals set and progress towards these goals, as part of a behaviour change intervention, in people with mild cognitive impairment: a secondary analysis.1 passage
• UK COVID-19 public inquiry and lessons from patient safety.1 passage
• UK COVID-19 public inquiry needed to learn lessons and save lives.23 passages
• UK guidelines for managing long-term effects of COVID-19.1 passage
• US-China health exchange and collaboration following COVID-19.18 passages
• Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.1 passage
• Ulcerative colitis.1 passage
• Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial.1 passage
• Ultra-processed foods and human health: the main thesis and the evidence.1 passage
• Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.1 passage
• Uncertainties over EU COVID-19 vaccine sharing scheme.5 passages
• Unclear conclusions on SARS-CoV-2 elimination versus mitigation - Authors' reply.1 passage
• Uncoupling vaccination from politics: a call to action.1 passage
• Understanding and approaching excessive daytime sleepiness.1 passage
• Understanding ethnic inequalities in the design and implementation of digital health interventions for cardiometabolic disease: a qualitative study.1 passage
• Understanding long COVID: a modern medical challenge.7 passages
• Understanding the drivers and consequences of early-onset type 2 diabetes.1 passage
• Understanding the use of media analysis in public health research through food tax debates (HEALTHEI Project): a scoping review.1 passage
• Understanding variants of SARS-CoV-2.5 passages
• Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales.1 passage
• Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.1 passage
• Universal health coverage for the poorest billion: justice and equity considerations - Authors' reply.2 passages
• Universal health coverage for the poorest billion: justice and equity considerations.5 passages
• Untangling the association between COVID-19 health literacy, trust in the pandemic response, and mental distress, during the COVID-19 pandemic in Ireland: a repeated cross-sectional study.1 passage
• Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.1 passage
• Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Updated trends in the global prevalence and burden of mental disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.1 passage
• Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation.1 passage
• Uptake of diabetes follow-up checks by minority community groups: a rapid review of the evidence for the CYMELL study.1 passage
• Uptake of monoclonal antibodies and antiviral therapies for COVID-19 in Scotland.1 passage
• Urgent care: disability, pandemic, and the value of a life.11 passages
• Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development.33 passages
• Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics.6 passages
• Use of co-production to explore food insecurity in adults with severe mental illness living in Northern England: a mixed-methods study.1 passage
• Use of the 2021 UK Medical Research Council guidance to refine the Women's Wellness with Type 2 Diabetes Programme: a mixed-methods study.1 passage
• Using EM data to understand COVID-19 pathophysiology - Authors' reply.5 passages
• Using EM data to understand COVID-19 pathophysiology.2 passages
• Using a participatory approach to encourage uptake of breast, colorectal, and cervical cancer screening for Scottish Muslim women: a pilot qualitative study.1 passage
• Using the Doughnut Economics framework to structure whole-system thinking in socioecological wellbeing with multidisciplinary stakeholders: an applied case study in Glasgow, Scotland.1 passage
• Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.1 passage
• VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.1 passage
• Vaccine approval before phase 3 trial results: a consequence of vaccine access inequity.2 passages
• Vaccine scarcity in LMICs is a failure of global solidarity and multilateral instruments.2 passages
• Vaccine shortages prompt changes to COVAX strategy.6 passages
• Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection.4 passages
• Vaccines can save children with non-preventable diseases - Authors' reply.1 passage
• Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial.1 passage
• Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: individual participant data meta-analysis of six randomised trials.1 passage
• Valvular heart disease: from mechanisms to management.1 passage
• Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.54 passages
• Venoarterial extracorporeal membrane oxygenation in patients with infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials.1 passage
• Venous thromboembolism.1 passage
• Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.1 passage
• Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.1 passage
• Vesicular monoamine transport inhibitors: current uses and future directions.1 passage
• Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Violence against health workers rises during COVID-19.5 passages
• Violence against health-care workers in the Philippines.3 passages
• Viral gastroenteritis.1 passage
• Visual outcomes associated with delay from trauma to surgery for open globe eye injury in Palestine: a retrospective chart review study.1 passage
• WHO COVID-19 therapeutic guidelines.1 passage
• WHO Living Guidelines on antivirals for COVID-19 are evidence-based.1 passage
• WHO and World Bank urge spending for UHC.6 passages
• WHO concerned over COVID-19 health-care waste.5 passages
• WHO international non-proprietary names: the need to distinguish COVID-19 vaccines.4 passages
• WHO shapes priorities for medicines? An analysis of the applicants and decision makers within the historical evolution of the WHO Model Lists of Essential Medicines.1 passage
• WHO team begins COVID-19 origin investigation.5 passages
• WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed.15 passages
• WHO/International Society of Hypertension risk prediction charts versus the UK Prospective Diabetes Study risk engine for cardiovascular risk assessment among patients with type 2 diabetes: a comparative study.1 passage
• Wakley-Wu Lien Teh Prize Essay 2020: passing the baton to the next generation of health workers.3 passages
• We need a global conversation on the 2020 Olympic Games.6 passages
• We need to make sure telecommuting does not exacerbate gender disparity.8 passages
• Wearing face masks in the community during the COVID-19 pandemic: altruism and solidarity.5 passages
• Wellbeing, symptoms of trauma, and personal resources in Palestinian professional helpers: a cross-sectional quantitative survey.1 passage
• Were pregnant women more affected by COVID-19 in the second wave of the pandemic?1 passage
• What are the obligations of pharmaceutical companies in a global health emergency?30 passages
• What can work and how? An overview of evidence-based interventions and delivery strategies to support health and human development from before conception to 20 years.1 passage
• What comes next in the COVID-19 pandemic?4 passages
• What is the association of COVID-19 with heart attacks and strokes?5 passages
• What is the right level of spending needed for health and care in the UK?49 passages
• What next for a COVID-19 intellectual property waiver?10 passages
• What's lurking in your electrocardiogram?5 passages
• When and which patients should receive remdesivir?7 passages
• When was mpox a public health emergency?2 passages
• Where is the next SARS-CoV-2 variant of concern?2 passages
• Which workplace health initiatives work, for whom, in what contexts, and how? A rapid realist review.1 passage
• Who pays and what pays off in sexual and reproductive health? A review of the cost and cost-effectiveness of interventions and implications for future funding and markets.1 passage
• Who's really in the loop? Rethinking oversight in AI-assisted health care.1 passage
• Why the global health community should support the EndSARS movement in Nigeria.4 passages
• Widespread implementation of a low-cost telehealth service in the delivery of antenatal care during the COVID-19 pandemic: an interrupted time-series analysis.53 passages
• Will the COVID-19 crisis catalyse universal health reforms?7 passages
• With the COVID-19 PHEIC over, what next?11 passages
• Work as a social determinant of health in high-income countries: past, present, and future.1 passage
• Work-related causes of mental health conditions and interventions for their improvement in workplaces.1 passage
• Workforce and workplace racism in health systems: organisations are diverse but not inclusive.8 passages
• World Heart Day 2021: COVID-19, digital health, and tackling cardiovascular disease.4 passages
• Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.1 passage
• Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants.33 passages
• Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.42 passages
• Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study.49 passages
• Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.40 passages
• X-linked hypophosphataemia.1 passage
• Yee-Sin Leo: a leader in Singapore's fight against infectious diseases.6 passages
• Yemen's health system has "collapsed", warns UN.5 passages
• Yes, democracy is good for our health-but which democracy?2 passages
• Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.1 passage
• Zero COVID in China: what next?9 passages
• Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.1 passage
• Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.1 passage
• Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.62 passages
• [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.1 passage
• [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.1 passage
• mRNA discoveries earn the 2021 Prince Mahidol Award.5 passages
• mRNA-based therapeutics: looking beyond COVID-19 vaccines.1 passage
• von der Leyen admits to COVID-19 vaccine failures.9 passages
• β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.1 passage
• β blockers switched to first-line therapy in hypertension.1 passage